Final programme - SIOG | International Society of …siog.org/files/public/siog_2017_final_programme_lr.pdfFinal programme 17th Conference of the International Society of Geriatric

Final programme

17th Conference of theInternational Society of Geriatric Oncology“From research to practice: incorporating geriatriconcology into patient care”

2017WARSAWPOLAND9-11 NOV.

ww

w.s

iog

.org

Member of

17th Conference of the International Society of Geriatric Oncology “From research to practice: incorporating geriatric oncology into patient care”

JOURNAL OF

GERIATRICONCOLOGY

OFFICIAL JOURNAL OF THEINTERNATIONAL SOCIETY OFGERIATRIC ONCOLOGY (SIOG)

Editor-in-Chief:Supriya Mohile, MD, Wilmot Cancer Institute,University of Rochester, USA The Journal of Geriatric Oncology is an international, multidisciplinary journal which is focused on advancing research in the treatment and survivorship of older adults with cancer, as well as literature relevant to education and policy development in geriatric oncology. The Journal of Geriatric Oncology publishes original research articles, review articles, clinical trials, treatment guidelines, short communications and letters to the Editor.

MAKE AN IMPACT! Get your research read.

! Publishing 6 issues per year!

! All accepted manuscripts are published online as Articles-in- Press within 2 weeks

! Open access publishing options available

! Worldwide dissemination through ScienceDirect: more than 65,000 articles downloaded in previous 12 months

Submit your paper online at http://ees.elsevier.com/jgo

Follow us on:@OncologyAdvance

Follow us on:facebook.com/oncologyadvance

For more information, please visit our website: www.geriatriconcology.net

2016 Impact Factor*

2.852*Journal Citation Reports

published byClarivate Analytics 2017

Final programme


3

Content

Venue floor plan 4

Welcome message 5

About SIOG 6-7

SIOG Board 7

SIOG Membership 8-9

What we do 10-11

Scientific and educational projects 12-13

General conference information 14-16

Scientific programme committee and track leaders 19

Faculty list 21

CME accreditation 22

SIOG Awards 23-25

Programme at a glance 26

Detailed programme by day 27-33

DAY 1 - Thursday, November 9, 2017 27-29

DAY 2 - Friday, November 10, 2017 30-31

DAY 3 - Saturday, November 11, 2017 32-33

Scientific posters 34-39

Sponsor acknowledgement 41

Industry sponsored satellite session programme 43

Scientific displays 43

Sponsor and exhibitor profiles 44-46

Faculty disclosures 48-49

The production and printing of the SIOG 2017 Final programme book has been kindly supported by


4

Final programme


Venue floor plan

Level WH (1):Registration area, session rooms, exhibition and poster area and coffee breaks.

Mezzanine level (M1 & M2):Speakers preview room, SIOG meeting room, ecancer interview room.

Downstairs:Hotel lobby, lunch buffet.


Plenary room

Break-out room

Exhibition, postersand coffee breaks

To Speaker Previewand smallermeeting rooms.

Downstairsto lunchareaR

egis

trat

ion

2017

WA

RS

AW

PO

LA

ND

9-1

1 N

OV

.

5

Final programme


Welcome addressDear Colleagues,

We are delighted to welcome you to Warsaw and to the 17th Annual Conference of the International Society of Geriatric Oncology!

SIOG’s mission is to foster the development of health professionals in the field of geriatric oncology, in order to optimize treatment of older adults with cancer. SIOG promotes these efforts in three important directions.

These are education, clinical practice and research. The Annual Conference fosters these efforts by bringing together international experts in geriatric oncology to present the latest evidence based research in the care of older adults with cancer and to provide an educational opportunity for clinicians. Every year, the members of various Committees of SIOG have worked hard to provide an outstanding and attractive programme to enhance and expand the scientific and educational sessions for a large number of international experts in geriatric oncology.

The worldwide population is aging, and cancer is a disease of aging. Thus, there is an anticipated rise in the number of older adults with cancer. In order to provide high quality, evidence-based care for this growing group of individuals, it is essential to meld the principles of Geriatrics and Oncology.

The theme of this year’s conference, “From research to practice: incorporating geriatric oncology into patient care” will set the tone for the presentations. Due to the dedicated work of multiple investigators in Geriatric Oncology, there is more and more data accumulating on patient assessment and therapeutics particularly over the past few years. There is a need to incorporate this new information into practice and help form the basis of future studies. The sessions will emphasize the optimal ways clinicians can use the information to better assess patients and help make treatment decisions to maximize benefit. Research presentations will also focus in this area.

The programme includes multidisciplinary sessions on solid tumours, haematological malignancies, new therapies, geriatric assessment, supportive care needs and an educational forum dedicated to nurses. The SIOG Annual Conference also includes special sessions in collaboration with industry to present the latest therapeutic data and their application to the older adults. SIOG is also dedicated to the development of allied health professionals and junior faculty with the attribution of the SIOG Nursing & Allied Health and the SIOG Young Investigator awards.

Warsaw, nurturing over 400 years of pride as a capital, is Poland’s largest city and an economic, political, and cultural centre. The city of Chopin is a bustling metropolis and features an unforgettable history. A city where a fourth of the terrain is covered by parkland and a city of culture for all tastes and budgets. As a visitor you will be delighted by the city’s diversity - from renaissance buildings to futuristic skyscrapers. Warsaw is the youngest European Old Town (on the UNESCO list) - rebuilt from the post-war rubble. As lovers of culture, art and entertainment, you will find much to enjoy in Warsaw: walking around the Old Town to see the Royal Castle with its two original Rembrandt canvases, as well as the Cathedral and the Mermaid Statue; enjoying a stroll along the Royal Route, packed with shops and charming cafes; visiting a prime example of social-realism architecture, the tallest building in Poland - the Palace of Culture and Science - with its viewing terrace on the 30th floor looking out over the entire city. Warsaw is a city to explore, full of surprises.

So once again welcome to Warsaw, welcome to the 2017 SIOG Annual Conference!

Stuart LichtmanSIOG President(2016-2018)

Ravindran KanesvaranScientific programme committee

Demetris PapamichaelCo-Chair Scientificprogramme committee

AgnieszkaJagiełło-GruszfeldLocal Chair

Siri RostoftScientific programme committee


6

Final programme


About SIOGWho we areToday, all oncologists are now geriatric oncologists. Treatment of cancer in older adults is more complex than younger persons because of comorbidities, competing risks of death, potentially altered treatment tolerance, and variable patient preferences. Older adults, also those with comorbidities, are willing to take a cancer treatment as long as it does not impact their function or their cognition. The International Society of Geriatric Oncology, or Societe Internationale d’Oncologie Geriatrique in French, hence the acronym SIOG, was founded in 2000 and was officially registered as a not-for-profit organisation under Swiss law in October 2012. It is a multidisciplinary society, including physicians in the fields of oncology and geriatrics, and allied health professionals and has a community of over 10,000 individuals and 1,500 members in more than 93 countries around the world. The founding members were: Paul Calabresi, Matti Aapro, Lazzaro Repetto, Martine Extermann, John Bennett, Riccardo Audisio, Lodovico Balducci and Silvio Monfardini.SIOG is and remains the leading force in channelling the knowledge and foresights of professionals to help determine the top priorities and actions to enhance the effectiveness of including geriatric protocols in the treatment and care of cancers of the elderly patients. SIOG represents over 4 million patients which are older than 65 years.

Our mission and visionChallenge: Major risk factor for cancer is age, and with the aging of the world population, a major epidemiologic challenge is ahead of us

Our goal: to foster the development of health professionals in the field of geriatric oncology, in order to optimize treatment of older adults with cancer

SIOG promotes efforts in 3 strategic directions: Education, clinical practice and research. These are addressed through the following goals and tools:

1. Education

2. Clinical practice

Goals Tools

Dissemination of knowledge to maintain a high common standard of healthcare in older cancer patients

• Journal of Geriatric Oncology (JGO)• SIOG Annual Conference• SIOG Regional Forums (APAC, LATAM,

USA, etc.)• SIOG Education handbooks on geriatric

oncology and online e-learning modules• SIOG Treviso Advanced Course, Education

Resources: SIOG-ASCO, Educational Geriatric Oncology Books

• Close collaboration with highly and well-known cancer educational organisations

• Constantly updated scientific resources that cover full spectrum of all relevant topics

Integrate geriatric oncology in the curricula for medical and nursing education to ensure a high standard of qualification for healthcare professionals

Address the shortage of specialist oncologists/geriatricians & allied health staff in geriatric oncology

Increase public awareness of the worldwide cancer in the elderly epidemic

Goals Tools

Integrate geriatric evaluation (including comorbidities) into oncology decision-making and guidelines • Comprehensive geriatric assessment

• SIOG Clinical guidelines* • SIOG Task Forces active in various fields

of geriatric oncology to produce position papers, consensus statements or clinical practice guidelines*

*Full list of SIOG Guidelines on www.siog.org

Improve the quality of prevention, diagnosis, treatment, and follow-up of older patients with malignancies

Address issues of access to care, including the needs of the caregiver

Develop interdisciplinary geriatric oncology clinics


7

Final programme


SIOG National RepresentativesThe International Society of Geriatric Oncology (SIOG) National Representative is the bridge between the Society’s core and its members around the globe. As the Society's spokespersons in their national respective countries, National and Regional Representatives act as ambassadors of SIOG's mission, sharing the same values and pursuing the same objectives, in the joint effort to benefit the specialty of geriatric oncology on a national as well as international level.

3. Research

SIOG Board members

Goals Tools

Develop, test and disseminate easy screening tools

• SIOG Geriatric Oncology Practice Centers Registry - research facilitating platform

• Geriatric Oncology grant for Young Researchers

Create a clear and operational definition of vulnerability/frailty applicable to oncology

Increase the relevance of clinical trials for older patients

Improve research in the field of geriatric oncology

Promote multidisciplinary, basic/translational research on the interface of aging and cancer

President and Chair of SIOG Conference Committee

Stuart Lichtman, Memorial-Sloan-Kettering Cancer Center, Commack, NY, United States

President-Elect Hans Wildiers, UZ Leuven, Leuven, Belgium

Immediate Past President Etienne Brain, Institut Curie (Hôpital René Huguenin), St Cloud, France

Treasurer Ravindran Kanesvaran, National Cancer Centre Singapore, Singapore

Chair Corporate Relations Committee Matti Aapro, Multidisciplinary Institute of Oncology, Genolier, Switzerland

Chair Fellowship, Nominating and Award Committee

Etienne Brain, Institut Curie (Hôpital René Huguenin), St Cloud, France

Chair Membership & NationalRepresentatives Committee

Kwok-Leung Cheung, University of Nottingham, Department of breast surgery, Nottingham, United Kingdom

Chair Publication Committee Gouri Shankar Bhattacharyya, Fortis Hospital, Kolkata, India

Chair Science & Education CommitteeTanya Wildes, Washington University School of Medicine, St. Louis, MO, United States

Chair Nursing & Allied Health Interest Group

Cindy Kenis, UZ Leuven, Leuven, Belgium

Observer - Chair Young SIOG Interest Group

Nienke de Glas, Leiden University Medical Center, Leiden, Netherlands

Ex Officio - Chief Executive Officer Laurence Verhagen, Geneva, Switzerland


8

Final programme


SIOG MembershipSIOG members share a passion to implicate clinical practice in the elderly. Current SIOG membership comprises over 1,500 individual members in 93 countries and continues to grow. Our current members are basic scientists, surgical oncologists, geriatricians, medical oncologists, radiation oncologists, psychologists, sociologists, nurses, nurse practitioners, and other healthcare professionals in active clinical practice interested in and/or involved in the management of older patients with cancer.

This year, SIOG wishes to acknowledge the membership anniversary of the following members who have been active within the society for 15, 10 and 5 years. SIOG thanks them for having contributed to the SIOG mission (improve cancer care for older adults), for having shown a continued commitment and for having supported our society for many years.

Ignazio Carreca (IT)Tom Kouroukis (CA)Stuart Lichtman (US)

Richard Schilsky (US)Catherine Terret (FR)

Franchette Van Den Berkmortel (NL)

Jorge AntunezDe Mayolo (US)Jean Archambault (CA)Gouri Shankar Bhattacharyya (IN)Etienne Brain (FR)Flordeliza Calacsan (IE)

James Clarkson (US)Elvira Colella (IT) Christine Dionne (CA)Regina Gironés Sarrió (ES)Steven Joniau (BE)Athanasios Karampeazis (GR)

Cindy Kenis (BE)Miroslav Kreacic (RS)Loic Mourey (FR)Anne Noonan (US)Elena Paillaud (FR)Siri Rostoft (NO)Gerald Sokol (US)

Nicolò MatteoLuca Battisti (IT/GB)Helen Boyle (FR)Thomas Bradley (US)Peggy Burhenn (US)Oscar Calderon (CL)Frank Cornélis (BE)Lissandra Dal Lago (BE)Nienke De Glas (NL)

Luiz Antonio Gil Junior (BR)Marije Hamaker (NL)Cristian Hartopeanu (NZ)Holly Holmes (US)Monique Huisman (NL)Manuel Jeschko (CH)Anand Karnad (US)Mandy Kiderlen (NL)

Jee Hyun Kim (KR)Jean Pierre Lobelle (BE)Ramona Moor (BE)Anita O'Donovan (IE)Angela Pugliesi Rinaldi (CH)Nicolas Signol (FR)Margaret Wallington (AU)Thomas Warkus (CA)

in 2017

in 2017

in 2017


9

Final programme


Membership benefitsn Access the Journal of Geriatric Oncology (JGO) - Pubmed indexed - 6 ANNUAL ISSUES (in print + online or online only, depending on membership status)

n Access the Critical Reviews in Oncology/Hematology (CROH) 12 ANNUAL ISSUES

n Get involved in SIOG educational activities, in the annual conference and governance

n Receive a discounted registration fee at SIOG Annual Conference

n Vote at the SIOG General Assembly and elect Board members

n Participate in Expert Task Forces

n Receive SIOG Newsletter

n Network with colleagues from all over the world and share your expertise

n Submit articles to the Journal of Geriatric Oncology (JGO), the only journal specifically dedicated to this area of medicine called geriatric oncology

n Benefit from reduced rates on some publications/books (e.g. ESMO Handbook of Geriatric Oncology, and other ESMO Handbooks)

In addition to the above mentioned benefits, members have the right to guide SIOG priorities and activities through voting at the General Assembly. The General Assembly is the supreme governing body of the society.

Join SIOG and help us achieve our goals!With your help, SIOG will be able to:n Improve the quality of prevention, diagnosis, treatment, and follow-up of older patients with malignancies

n Develop, test and disseminate easy screening tools.

n Increase public awareness of the worldwide cancer in the elderly epidemic

Becomea member now!More information athttp://siog.org/content/join-siog


10

Final programme


What we do

NURSING &ALLIED HEALTH

Nursing & Allied Health (NAH) Interest GroupThe core responsibility of this interest group is to develop and promote, in accordance with the SIOG policies and strategy determined by the Board of Directors, excellence in geriatric oncology nursing through the SIOG strategic directions: education/clinical practice, research and advocacy. The NAH interest group shall oversee the nursing and allied health related activities included in all SIOG scientific, educational and advocacy related projects.

Interest Group Leadership 2016-2018 Cindy Kenis (BE) - Chair Petra Stolz Baskett (NZ) - Vice-ChairPeggy Sue Burhenn (US) Karis Kin-Fong Cheng (SG) Ginah Nightingale (US) Martine Puts (CA) Laurence Verhagen (CH) - ex-officio

Nursing & Allied Health Interest Group activities during SIOG 2017SIOG Nursing and Allied Health Interest Group & EONS Joint session Thursday, November 9 - 16:15-17:45 - Warsaw IIICaring for older patients with cancer: experiences, assessment and management Chair: Cindy Kenis (BE)

16:15-16:35 Caring for older patients with cancer with a patient-centred approach: does it impact health status, quality nursing care and trust in nurses? Andreas Charalambous (CY)

16:35-16:55 Smart phone real time symptom assessment and management Lisa McCann (GB)

16:55-17:15 Falls in older patients with cancer: assessment and management Schroder Sattar (CA)

17:15-17:35 Dignity in care: developing, adapting and implementing the dignity care intervention (DCI) in community care for older persons in palliative phase Ulrika Östlund (SE)

17:35-17:45 Discussion and question

SIOG 2017 Nursing & Allied Health Investigator AwardThis award aims to recognise significant contributions from new investigators in geriatric oncology nursing and allied professions at international level. Selected for the outstanding quality of their work, three Nursing & Allied Professional Investigators will be competing for this SIOG Award. Finalists are: Ramona Moor (BE), Mackenzi Pergolotti (US) and Kristen Haase (CA). See page 23 for their profiles.

The SIOG 2017 Nursing & Allied Health Investigator award will be handed out during the SIOG Presidential session on Saturday, November 11, 2017 at 11:30 in Room Warsaw IV & V.


11

Final programme


YOUNGSIOG

Young SIOG Interest GroupYoung SIOG is a SIOG Interest Group that was established by young clinicians and researchers, members of SIOG, who are working in the field of geriatric oncology.This interest group shall develop and promote, in accordance with the SIOG policies and strategy determined by the Board of Directors, excellence in geriatric oncology nursing through the SIOG strategic directions: education/clinical practice, research and advocacy.The Young SIOG interest group shall oversee the young researchers in geriatric oncology related activities included in all SIOG scientific, educational and advocacy related projects.

Interest Group Leadership 2017-2018Nienke de Glas (NL) - ChairNicolò Matteo Luca Battisti (IT & GB) - Vice-ChairCapucine Baldini (FR)Mandy Kiderlen (NL) Melissa Loh (MY & US) Enrique Soto Perez de Celis (MX & US)Laurence Verhagen (CH) - ex-officio

Young SIOG activities during SIOG 2017Young SIOG Research sessionThursday, November 9, 2017 - 12:15-13:15 - Warsaw III

This new session will include 3 research proposals that will be presented by young SIOG members, after which a panel of experienced researchers (Martine Extermann (US) & Etienne Brain (FR)) will comment on the research strategy, methodology and chances and opportunities. We will have a plenary discussion on how your proposal may be improved and carried out.

Young SIOG Poster discussionFriday, November 10, 2017 - 11:00-11:30 - In the back of the poster area

Check out the best prospective and innovative studies for each of our five SIOG 2017 scientific tracks (P030, P038, P043, P067, P104) led by Arti Hurria and Martine Extermann.

Young SIOG Research sessionThursday, November 9 - 12:15-13:15 - Warsaw III

This new session will include 3 research proposals that will be presented by young SIOG members, after which a panel of experienced researchers (Martine Extermann (US) & Etienne Brain (FR)) will comment on the research strategy, methodology and chances and opportunities. There will be a plenary discussion on how the proposal may be improved and carried out.

12:15-12:25 Research proposal 1: Predicting treatment morbidity from sorafenib in elderly patients with advanced hepatocellular carcinoma (HCC) with varying liver dysfunction Sukeshi Patel Arora (US)

12:25-12:35 Panel discussion Martine Extermann (US) and Etienne Brain (FR)

12:35-12:45 Research proposal 2: Peer-questioned assessment of premorbid geriatric function in patients with AML and its impact on survival and treatment tolerability Nina Neuendorff (DE)

12:45-12:55 Panel discussion Martine Extermann (US) and Etienne Brain (FR)

12:55-13:05 Research proposal 3: Oncologists’ perspectives of the survivorship care plans for older breast cancer survivors Jessica L. Krok (US)13:05-13:15 Panel discussion Martine Extermann (US) and Etienne Brain (FR)

Young SIOG General assemblySaturday, November 11, 2017 - 12:45-13:45 - Warsaw IV & VChairs: Nienke de Glas (NL) and Mandy Kiderlen (NL)

Young SIOG is a SIOG Interest Group that reaches out to all young clinicians and researchers who work in all disciplines that deal with cancer in older patients. In this Young SIOG session ongoing and future projects of the group will be discussed. Members will get the opportunity to give feedback and to bring new ideas to the group.

SIOG 2017 Young Investigator AwardTo promote research in the field of geriatric oncology and support the career development of the new generation of experts, SIOG will recognize three Young Investigators for their outstanding work. Award finalists are: Kah Poh Loh (US), Ishwaria Subbiah (US) and Melisa Wong (US). See page 24 for their profiles.

The SIOG 2017 Young Investigator Awards will be handed out during the SIOG Presidential session on Saturday, November 11, 2017 at 11:30 in Room Warsaw IV & V.


12

Final programme


Scientific and educational projectsTaskforcesThe International Society of Geriatric Oncology has as one of its major objectives to improve treatment and care for elderly patients with cancer. SIOG has developed a series of experts’ recommendations/guidelines published in international scientific journals (Lancet Oncology, Annals of Oncology, JCO, EJC, etc.) on the following topics.Please go to our website www.siog.org for full information.

The taskforces have several published documents that they produce: n Peer-reviewed published articles with the official recommendations n Newsletters about the meeting(s) preparing the recommendations n Abstracts sent in to international conferencesn Presentations in programs of scientific meetings n Monographs with relevant educational topics

At the moment SIOG is preparing guidelines on the following topics:n Anti-HER2 targeted treatments in the elderly with breast cancer n The treatment of bladder cancer in older cancer patientsn The management of elderly metastatic Renal Cell Carcinoma (mRCC) patientsn Study to estimate the toxicity, dose-intensity, and benefit of anti-EGFR-based treatment in patients with advanced colon cancer according to agen Quality of life in older cancer patientsn The impact of nutrition in the management outcomes of older adults with gastrointestinal cancersn Corticosteroids and cancer treatments in older patientsn The treatment of Acute Promyelocytic Leukemia (APL) in older patients

E-learning modulesThe International Society of Geriatric Oncology, in a strategic partnership with ecancer, has collaborated to develop a series of online educational activities specifically addressing the special considerations that apply to managing the older patient with cancer. These free, continuing education activities aim to identify patient- and disease-related factors that may complicate treatment, and share expert perspectives about strategies and tools for providing optimal care for older patient with cancer. Check out our website www.siog.org for full details.

ESO / SIOG e-sessionsESO in collaboration with SIOG has developed 2 e-sessions in previous years:Geriatric Oncology: a multidisciplinary approach in action and Geriatric Oncology: Why is it so important in our older breast cancer patient? Both sessions were conducted by Etienne Brain (Hôpital René Huguenin / Institut Curie, Saint-Cloud, France) and Marije Hamaker (Diakonessenhuis Utrecht, Utrecht, The Netherlands). Find out more at http://siog.org/content/e-learningexperts-interviews


13

Final programme



GERIATRICONCOLOGY

TREVISO, ITALYJUNE 28-JULY 1, 2017

ADVANCEDCOURSE

SIOG Advanced Course in Geriatric OncologyThis course aims to train professionals in the management of elderly cancer patients, providing specific skills in assessment, care pathways and therapeutic choices about the elderly patients with cancer. The goal is to develop the general principles of both geriatric and oncology medicine that are useful to treat elderly cancer patients. The course is organised in conjunction with the Universita Cattolica del Sacro Cuore. The next edition will be held in Treviso, Italy from June 27 to 30, 2018.

The 2017 Advanced Course in Geriatric Oncology successfully took place on June 28 to July 1, 2017 in Treviso, Italy and was attended by 34 participants from all over of the world.

Come and check out our dedicated SIOG Advanced Course poster area in poster hall where the 2017 course students have the possibility to showcase their planned projects following the course.

The following activities are organized as part of phase II of the SIOG 2017 Advanced Course in Geriatric Oncology:

Welcome coffee and follow up with course faculty and studentsn Thursday, November 9, 2017, 10:00-10:30 n Room: Dedicated area in the foyer of the exhibition and poster hall, in front of the registration desk.Meet up with your fellow students and the faculty to share feedback, expectations, improvements, unmet needs, etc.

Please note that this gathering is for the course students and faculty only.

Advanced Course Poster Walkn Friday, November 10, 2017, 15:30-16:00 n Room: Dedicated poster area in exhibition hall Course students will have the possibility to discuss their poster with the Geriatric Oncology community present at the conference and showcase planned projects after the course.

Final wrap up and knowledge assessment of the Advanced Course n Saturday, November 11, 2017, 10:30-11:30 n Room: Room 1 (Mezzanine level)Multiple choice examination related to the SIOG 2017 Annual Conference plenary sessions, which will conclude the course and allow students to receive their final diploma.

IMPORTANT: This assessment is mandatory for all course students in order to obtain the final diploma and CME certificate of the Advanced Course.

Interested in attending the next edition of ourSIOG Advanced Course in Treviso, Italy?

Please contact [email protected] to register your interest.Admission will open in January 2018 and full information will be available

on our website www.siog.org in due course.

14

Final programme


General informationConference venueHilton Warsaw Hotel & Convention Centre Grzybowska 63, Warsaw, 00-844, Poland www.hilton.com/warsaw

All scientific sessions will take place in the rooms Warsaw III and Warsaw IV & V. The poster and scientific displays as well as coffee breaks will take place in Warsaw I & II. All rooms located on the WH Level - one level above the hotel lobby. Please refer to the venue floor plan on page 4 for more information.

RegistrationThe registration desk is located in the foyer of the session rooms on level WH and will be open at the following hours:n Thursday, November 9 07:00-19:00n Friday, November 10 07:30-18:30n Saturday, November 11 07:30-17:00

Onsite registrationn SIOG Member EUR 725n Non-member EUR 945n SIOG Member Trainee/Nurse/Patient advocate EUR 420n Non-member Trainee/Nurse/Patient advocate EUR 680

Cash and credit card payments will be possible at the registration desk in Euro.

Registration feeThe registration fee includes:n Access to all scientific sessionsn Access to the posters and scientific display arean Access to online abstract book (searchable pdf format) supplement of the Journal of Geriatric Oncology, which will be indexed and referenced in PubMed and Science Directn Access to conference proceedings after the conferencen Conference materialn Morning and afternoon coffee breakn Poster welcome reception on Thursday, November 9 at 18:00n Free WIFI accessn 23% VAT (Value Added Tax)

SIOG MembershipTo become a SIOG member, please complete the online membership form which can be found on the SIOG website:www.siog.org/content/join-siog

Name badgesAll participants are requested to wear their name badges throughout the conference. If a badge is lost or forgotten, an administrative fee of EUR 80 will be charged for the reprint of the badge after identity verification (passport, driving license or other recognized identification document).

NEW I SIOG 2017 has been chosen for a trial to test a new generation of delegate badges. In future, these will enable you to exchange information amongst each other, vote during sessions, join specific groups of like-minded delegates or interact during a congress through colored lighting on the badge, and much more. For the SIOG conference, this trial will only consist in localization of participant flow within specific zones of the conference venue - such as the poster, catering and session areas. As a participant at the conference, you will not be impacted. All tracked data will be anonymous and only has a very small operating radius inside the conference rooms and the venue.We simply ask you to, please, ensure that you return your badge either to the registration area or to the clearly designated collection points - which will be located near to the exits of the conference venue - before your final departure from the event. These badges will be recycled.


15

Final programme


Certificate of attendancePlease complete the attendance form and bring it back to the registration desk starting Friday, November 10, 2017 as of 16:00. You will then receive your certificate.

Exhibition and scientific displaysSelected pharmaceutical and medical societies have been invited to exhibit their services.The exhibition is located in Warsaw I & II on the WH Level.

Exhibition opening hoursn Thursday, November 9 10:00-19:00n Friday, November 10 09:30-17:30n Saturday, November 11 09:30-15:00

Speaker’s preview room opening hoursn Wednesday, November 8 16:30-18:30n Thursday, November 9 07:30-19:00n Friday, November 10 07:30-18:30n Saturday, November 11 07:30-16:00

Scientific poster displayPosters will be displayed in the poster area during the whole duration of the conference within the exhibition area. Presenting authors are kindly requested to be present at their poster for presentation on:n Thursday, November 9 10:00-10:30 / 12:30-13:15 15:45-16:15 and 18:00 for the Poster Welcome Receptionn Friday, November 10 11:00-11:30 / 13:15-14:00 and 15:30-16:00n Saturday, November 11 10:00-10:30 and 12:30-13:15

Hanging: Thursday, November 9 - 08:30-10:00

Dismantling: Saturday, November 11 - as of 16:00. Posters not removed after 17:00 will be discarded.

ecancer - expert interviewsFollowing the success of previous years, ecancer the leading oncology channel, will again provide highlights of SIOG 2017 through scientific interviews of our conference experts. Stay tuned for when the interviews and webinars will be made available on SIOG and ecancer websites.

This service is kindly supportedby an unrestrictededucational grant from

Poster welcome receptionThursday, November 9 as of 18:00 within the poster area in rooms Warsaw I & II.This scientific and networking event is offered by SIOG to allow all delegates and friends of SIOG to exchange best practices and facilitate collaborations.

Coffee breaks and lunches All coffee breaks will be served in Warsaw I & II on the WH Level.The lunch buffet is located on the ground level. If you have ordered lunch with your registration your conference badge will emit a coloured light signal upon entering the lunch area to indicate to the staff at the door that you have indeed purchased lunch for that day. Lunch will be served between 12:00 and 14:00 on 8, 9 and 10 November. Additional lunches can be purchased at the registration desk, subject to availability.


16

Final programme


SIOG 2017 Networking dinnerThe SIOG 2017 Networking dinner will take place at the U Kucharzy Restaurant; Długa 52, Warsaw on Friday, November 10, 2017 from 19:30-22:30. If you have purchased access to the dinner your conference badge will emit a coloured light signal upon entering the dinner venue to indicate to the staff at the door that you are registered for the dinner. Do not miss out on what promises to be a fantastic evening once again. Meet in the hotel lobby at 18:45 to be guided to the dinner venue (via public transport; tickets included).

Itinerary to the restaurant:https://goo.gl/maps/jLdq8u3v5C12or scan this QR code to obtain the directionsdirectly on your phone:

Conference languageThe official conference language is English. There will be no simultaneous interpretation available.

MessagesYou may leave and collect messages at the registration desk.

WiFiWe are pleased to offer complimentary WIFI access to all SIOG 2017 participants.Network Name: Hilton HonoursPassword: SIOG2017

Online abstract bookDelegates of the 2017 SIOG Annual Conference can enjoy complimentary full text access to the Journal of Geriatric Oncology from the first day of the conference, November 9 until December 2017.

For your complimentary access, simply go to http://siog2017.elsevierdigitaledition.com/

Onsite abstract printingPrinting of abstracts is possible at the Elsevier printing station close to the registration area and session rooms.

NEW I Q&A and session rating toolBrand new for SIOG 2017, a live Q&A tool will be used for all the Conference sessions. The tool is completely web based, no download is required. It will allow you to ask your questions via your phone, tablet or laptop during the session right as you think of them. Your question will then immediately appear on the tool, where you will be able to view all the other attendees’ questions and/or vote for the questions that you find most relevant or interesting, even if you do not have any question of your own.At the end of the session, all of the questions will be projected on screen, and the ones with the most votes will be answered first, ensuring that the speakers and moderators address the matters that are most relevant to the audience.You will also be able to rate the session directly within the tool, via the rating button that will automatically appear a few minutes prior to end of the session. Share your feedback with us in a few seconds right there and then to help us keep on improving the content of the next SIOG Conference.

To access the tool, simply enter this link into your browser:www.siog2017.cnf.io or scan the following QR code

DisclaimerThe conference organizers accept no liability for any injury or damage (including personal injury or for any loss, cost or damage to property belonging to conference participants) arising out of or in connection with the conference, including but not limited to during any activities. It is recommended that participants, as well as companies, arrange their own personal health, accident, travel, property loss/damage insurance or any other necessary insurance. MCI Suisse SA acts as agents and cannot be held responsible for any loss, cost, injury or damage to any person or property whatever the cause may be.

Kindly be informed that November 11 is Polish National Independence Day. Large crowds may gather for celebrations in the Warsaw City Centre or in the Old Town. Please take normal precautions and pay extra attention to your personal belongings when walking around Warsaw on this day.


General information (...continued)

17

Final programme


Oncologists and Geriatricians need to work together!Here is how:

Join our unique CME accredited training programme lead by international experts in the field of geriatrics AND oncology designed to provide specific skills in assessment, care pathways and therapeutic choices about the elderly patients with cancer in order to provide the basis of the assessment and the multi-dimensional approach that should be applied to elderly cancer patients.

This 2-phase advanced course is addressed to professionals in the management of elderly cancer patients who will acquire knowledge on the general principles of cancer treatment as a multidisciplinarity with case based programmes, discussions and debates in geriatrics for clinical oncologists as well as in clinical oncology for geriatricians.

n Admission process opens January 8, 2018

n Admission process closes February 9, 2018

n Notification of acceptance beginning March 2018

Phase 1 3,5-day course in Treviso, Italy from June 27-30, 2018

Phase 2 3 days at the SIOG 2018 Annual Conference in Amsterdam, Netherlands from November 16-18, 2018

Join us in Treviso, find your mentor, be part of an international network and become the bridge between the oncological and geriatric teams in your institution.

Mark your calendar!

Scientific programme committee:Course director: Silvio Monfardini (IT)Course co-director: Etienne Brain (FR)Course coordinator: Giuseppe Colloca (IT)Members: Martine Extermann (US)Pierre Soubeyran (FR)Tanya Wildes (US)Laurence Verhagen (CH) - ex-officio

Honorary members:Riccardo Audisio (GB)Lodovico Balducci (US)

Preliminary faculty list:Matti Aapro (CH)Etienne Brain (FR)Antonella Brunello (IT)Kwok-Leung Cheung (GB)Giuseppe Colloca (IT)Marije Hamaker (NL)Martine Extermann (US)Andrea Luciani (IT)Silvio Monfardini (IT)Anita O’Donovan (IR)Siri Rostoft (NO)Pierre Soubeyran (FR)Tanya Wildes (US)

Find out more andsign up at www.siog.org

Places are limited!

Pending applications for auspices and endorsement:

The programmeis an ESOrecommendedactivity and is heldwith the support of

Save the date!

18th Conference of theInternational Society of Geriatric Oncology

2018AMSTERDAMTHE NETHERLANDS16-18 NOV

Member of

ww

w.s

iog

.org

Save the date!

GERIATRICONCOLOGY

TREVISO, ITALYJUNE 27-30, 2018

ADVANCEDCOURSE

18

Final programme


The book series

Interdisciplinary Topics in Gerontology and GeriatricsSeries Editor: T. Fulop (Sherbrooke, Que.)

To keep up-to-date on what is being published in gerontology, subscribe to our Alert-Service at www.karger.com/mykarger K

I174

33

International Journal of Experimental, Clinical, Behavioural, Regenerative and Technological Gerontology


Editor: G. Wick (Innsbruck)

www.karger.com/ger

Vol. 42

HIV and AgingEditors: Brannan-Ing, M. (New York, N.Y.); DeMarco, R. (Boston, Mass.)

Vol. 41

Frailty in AgingBiological, Clinical and Social ImplicationsEditors: Theou, O. (Halifax, N.S.); Rockwood, K. (Halifax, N.S.)

Vol. 40

Aging and Health – A Systems Biology PerspectiveEditors: Yashin, A.I. (Durham, N.C.); Jazwinski, S.M. (New Orleans, La.)

Vol. 39

AgingFacts and TheoriesEditors: Robert, L. (Paris); Fulop, T. (Sherbrooke, Que.)

Fore more information and easy ordering

www.karger.com/intgg

Interdisciplinary Topics inGerontology and Geriatrics

Editor: T. Fulop

Vol. 42

HIV and AgingEditors

M. Brennan-IngR.F. DeMarco

Medical and Scientific Publishers


Editor: T. Fulop

Vol. 41

Frailty in AgingBiological, Clinical and Social Implications

Editors

O. TheouK. Rockwood

Interdisciplinary Topics in Gerontology

Editor: T. Fulop

Vol. 40

Aging and Health A Systems Biology Perspective

Editors

A.I. YashinS.M. Jazwinski

Inflammation

DNA damage/genomic instability

ROS Senescence

Mitochondrial dysfunction

Proteostasis

Epigenetic factorsGrowth signaling

Cancer

Senescence

Neurodegeneration

Atherosclerosis

Frailty Tissuedegeneration

Metabolic disease

Obesity

Inflammation

IGFNFκ-B

Nrf2

mTOR

Mitohormesis

FOXO

Sources of homeostaticstress

Geneticregulators oflongevity

Aging andage-relateddisease

Obesity

Inflammation



Editor: T. Fulop

Vol. 39

AgingFacts and TheoriesEditors

L. RobertT. Fulop

F R E E R A D I C A L S

C E L L AG I N GE N V I R O N M E N T

E V O LU T I O N

G E N E T I C S

LO N G E V I T Y

BMA Medical Book Awards 2017 ‘highly commended’

in Medicine

19

Final programme


Scientific programme committeeStuart Lichtman (US) - ChairDemetris Papamichael (CY) - Co-ChairAgnieszka Jagiełło-Gruszfeld (PL) - Local chairMatti Aapro (CH)Ravindran Kanesvaran (SG)Siri Rostoft (NO)Laurence Verhagen (CH) - Ex officio

Track leaders

Track 1: Solid tumours in the elderly and basic science

Nienke de Glas (NL)Roman Dubianski (PL)Robert Glynne-Jones (GB)Anne Horgan (IE)Karis Kin-Fong Cheng (SG)William Tew (US)Giampaolo Ugolini (IT) Track 2: Haem malignancies in the elderly and basic science

Valentin Goede (DE)Kah Poh Loh (US)Petra Stolz-Baskett (NZ)Tanya Wildes (US)

Track 3: Supportive and palliative care

Nicolo Matteo Luca Battisti (IT/GB)Holly Holmes (US)Fumio Nagashima (JP)Ginah Nightingale (US)Adam Pluzanski (PL)Carla Ripamonti (IT) Track 4: Modern diagnostics and therapeutic areas

Shabbir Alibhai (CA)Fabio Gomes (PT/UK)Michael Jaklitsch (US)Cindy Kenis (BE)Hervé Le Caer (FR)Anna Niwinska (PL)Janice Tsang (CN)Hans Wildiers (BE)

Track 5: Geriatric assessment, nursing/allied health and patient care

Katarzyna Broczek (PL)Tania Kalsi (GB)Mandy Kiderlen (NL)Marcin Maczkiewicz (PL)Martine Puts (CA)Barbara Van Leeuwen (NL)Wee-Kheng Soo (AU)

The book series

Interdisciplinary Topics in Gerontology and GeriatricsSeries Editor: T. Fulop (Sherbrooke, Que.)

To keep up-to-date on what is being published in gerontology, subscribe to our Alert-Service at www.karger.com/mykarger K

I174

33



Editor: G. Wick (Innsbruck)

www.karger.com/ger

Vol. 42

HIV and AgingEditors: Brannan-Ing, M. (New York, N.Y.); DeMarco, R. (Boston, Mass.)

Vol. 41

Frailty in AgingBiological, Clinical and Social ImplicationsEditors: Theou, O. (Halifax, N.S.); Rockwood, K. (Halifax, N.S.)

Vol. 40

Aging and Health – A Systems Biology PerspectiveEditors: Yashin, A.I. (Durham, N.C.); Jazwinski, S.M. (New Orleans, La.)

Vol. 39

AgingFacts and TheoriesEditors: Robert, L. (Paris); Fulop, T. (Sherbrooke, Que.)

Fore more information and easy ordering

www.karger.com/intgg


Editor: T. Fulop

Vol. 42

HIV and AgingEditors

M. Brennan-IngR.F. DeMarco

Medical and Scientific Publishers


Editor: T. Fulop

Vol. 41

Frailty in AgingBiological, Clinical and Social Implications

Editors

O. TheouK. Rockwood


Editor: T. Fulop

Vol. 40

Aging and Health A Systems Biology Perspective

Editors

A.I. YashinS.M. Jazwinski

Inflammation

DNA damage/genomic instability

ROS Senescence

Mitochondrial dysfunction

Proteostasis

Epigenetic factorsGrowth signaling

Cancer

Senescence

Neurodegeneration

Atherosclerosis

Frailty Tissuedegeneration

Metabolic disease

Obesity

Inflammation

IGFNFκ-B

Nrf2

mTOR

Mitohormesis

FOXO

Sources of homeostaticstress


Aging andage-relateddisease

Obesity

Inflammation



Editor: T. Fulop

Vol. 39

AgingFacts and TheoriesEditors

L. RobertT. Fulop

F R E E R A D I C A L S

C E L L AG I N GE N V I R O N M E N T

E V O LU T I O N

G E N E T I C S

LO N G E V I T Y

BMA Medical Book Awards 2017 ‘highly commended’

in Medicine


20

Final programme


SGZ_SIOG_Congress_Program_Book_ad.indd 1 9/26/2017 3:56:23 PM

21

Final programme


SGZ_SIOG_Congress_Program_Book_ad.indd 1 9/26/2017 3:56:23 PM

Faculty listFor full biographies of our SIOG 2017 faculty please visit our website.

Shabbir Alibhai (CA)Daniel Anaya (US)Lodovico Balducci (US)Gouri Shankar Bhattacharyya (IN)Paolo Bossi (IT)Federico Bozzetti (IT)Etienne Brain (FR)Katarzyna Broczek (PL)Krzysztof Bujko (PL)Philippe Caillet (FR)Andreas Charalambous (CY)Kwok-Leung Cheung (GB)Junsung Choi (US)Giuseppe Colloca (IT)Lore Decoster (BE)Nienke de Glas (NL)Eleni Efstathiou (GR/US)Martine Extermann (US)Jessica Frakes (US)Walter Gianni (IT)Rob Glynne-Jones (GB)Valentin Goede (DE)Fabio Gomes (PT/GB)Carlos Gomez-Roca (FR)Alastair Greystoke (GB)Tomasz Grodzicki (PL)Agnieszka Gruzfeld-Jagiello (PL)Marije Hamaker (NL)Sarah Hoffe (US)Arti Hurria (US)Muhammad Shahid Iqbal (GB)Michael Jaklitsch (US)Theodora Karnakis (BR)Charles Kelly (GB)Cindy Kenis (BE)

Mandy Kiderlen (NL)Karis Kin-Fong Cheng (SG)Beatriz Korc-Grodzicki (US)Domenico La Carpia (IT)Stuart Lichtman (US)Rosa Liperoti (IT)Kah Poh Loh (US)Ron Maggiore (US)Lisa McCann (GB)Supriya Mohile (US)Nicolas Mottet (FR)Karen Mustian (US)Shane O'Hanlon (GB)Ulrika Östlund (SE)Demetris Papamichael (CY)Christopher Plummer (GB)Adam Pluzanski (PL)Martine Puts (CA)Morten Quist (DK)Carla Ripamonti (IT)Jarred Rosenberg (CA)Siri Rostoft (NO)Harm Rutten (NL)Schroder Sattar (CA)Armin Shahrokni (US)Iwona Skoneczna (PL)Pierre Soubeyran (FR)Reinhard Stauder (AT)Petra Stolz Baskett (NZ)William Tew (US)Diane Tilmant-Tatischeff (FR)Barbara Van Leeuwen (NL)Tanya Wildes (US)Hans Wildiers (BE)


22

Final programme


CME accreditationThe SIOG 2017 Annual Conference, Warsaw, Poland, 09/11/2017-11/11/2017 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 16 European CME credits (ECMEC®s).

Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 CreditsTM. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

The SIOG 2017 Scientific programme under the auspices, endorsed or recommended by:


23

Final programme


SIOG AwardsSIOG 2017 Nursing & Allied Health (NAH) Investigator AwardThis award aims to recognise significant contributions from new investigators in geriatric oncology nursing and allied professions at international level. Selected for the outstanding quality of their work, three Nursing & Allied Professional Investigators will be competing for this SIOG Award.

Meet our 2017 Award finalists:

The SIOG 2017 Nursing & Allied Health Award will be handed out during the Presidential Session on Saturday, November 11 at 11:30 in room Warsaw IV & V.

KRISTEN HAASE (CA)Assistant professor tenure-stream, Lawrence S. Bloomberg Faculty of Nursing, University of Toronto, Toronto Canada.

Kristen Haase is a Registered Nurse and PhD candidate at the School of Nursing, University of Ottawa, in Ottawa, Canada and an Assistant Professor at the University of Saskatchewan. Her research focuses on the patient experience with cancer, with particular interest in two areas: patient-healthcare professional interactions and the use of technology to optimize self-management in older adults. Kristen has clinical expertise in medical and surgical nursing, and the use of simulation in nursing education. Kristen has held fellowships and awards from the Nursing Intervention Research Group of Quebec, the Psychosocial Oncology Research Training Program, funded by the Canadian Institutes of Health Research, and the International Society of Nurses in Cancer Care. Kristen has held funding as a principal investigator and co-applicant on research grants from several organizations, including the Canadian Association of Nurses in Oncology, and the Saskatchewan Health Research Foundation.

Her abstract (O11) Older adults’ use of cancer-related internet information: conclusions and future directions from a qualitative study will be presented on Thursday, November 9 at 16:45 in room Warsaw IV & V.

RAMONA MOOR (BE)Ramona has achieved her Bachelor in Nursing at the Armand Weber Nursing School, in Verviers, Belgium and her Master in Public Health Sciences at the Université Catholique de Louvain, in Brussels, Belgium. Since nearly eight years, she works as a Clinical Research and Care Coordinator in the field of Geriatric Oncology (GO) at the Cliniques Universitaires Saint-Luc in Brussels. In collaboration with the other members of her multidisciplinary team, she has created a clinical pathway dedicated to older patients with cancer in her institution. Thanks to financial support of the Belgian Cancer Plan, she participates in several studies and she coordinates a multicentric observational study focusing on the benefits of specific care for older cancer patients. Ramona is particularly interested in multidisciplinarity, geriatric assessment, active implementation of geriatric interventions, cancer treatment adaptation, perceived quality of life and patient’s satisfaction.

Her abstract (O22) Impact of a specific multidisciplinary geriatric oncology clinical pathway on the number and types of implemented geriatric interventions will be presented on Friday, November 10 at 12:00 in room Warsaw IV & V.

MACKENZI PERGOLOTTI (US)Assistant Professor, Department of Occupational Therapy, College of Health and Human Sciences, Colorado State University, Fort Collins, CO USA

Mackenzi Pergolotti is an assistant professor in the Department of Occupational Therapy, in the College of Health and Human Sciences, at Colorado State University. As an occupational therapist, Dr. Pergolotti worked at the Memorial Sloan-Kettering Cancer Center (MSKCC) developing programs aimed to better address the needs of multiple populations. Realizing the impact of cancer rehabilitation provided at centers like MSKCC, she was driven to build the evidence-base and programs for cancer rehabilitation nation-wide. Previously, at the University of North Carolina at Chapel Hill, Dr. Pergolotti worked collaboratively with researchers from the Cecil G. Sheps Center for Health Services Research, the Gillings School of Global Public Health, in the Department of Health Policy and Management, the Cancer Research Outcomes Group and the Geriatric Oncology Program at the Lineberger Comprehensive Cancer Center through pre-doctoral and post-doctoral fellowships to look at utilization, access to and the quality of cancer rehabilitation. Her pre doctoral fellowship was supported by a T32 National Research Service Award (NRSA) Institutional Training Grant from the Agency for Healthcare Research and Quality (AHRQ), and her post-doctoral fellowships were funded through an R25 Cancer Care Quality Training Program from the National Cancer Institute.

Her abstract (O04) The care program: occupational and physical therapy for older adults with cancer will be presented on Thursday, November 9 at 14:15 in room Warsaw IV & V.


24

Final programme


SIOG 2017 Young Investigator AwardTo promote research in the field of geriatric oncology and support the career development of the new generation of experts, the Young SIOG Investigator Award will recognize three young investigators for their outstanding work.

Meet our 2017 Award finalists:

The SIOG 2017 Young Investigator Award will be handed on during the Presidential Session on Saturday, November 11 at 11:30 in room Warsaw IV & V.

KAH POH (MELISSA) LOH (US)Dr. Loh is originally from Malaysia. She graduated from the Royal College of Surgeons in Ireland and completed her internship and residency at Baystate Medical Center/Tufts University School of Medicine. She is currently pursuing a fellowship in combined geriatrics and hematology/oncology at University of Rochester/Strong Memorial Hospital in the USA. At the University of Rochester, she works very closely with her mentors, Dr. Supriya Mohile and Dr. Karen Mustian, in multiple projects related to geriatric oncology. Her current research interests include three areas: 1) decision-making process in older adults with acute myeloid leukemia; 2) the effects of exercise in older adults with cancer; and 3) information technology in coordinating care in older adults with cancer. She hopes to become a future clinician, researcher and educator.

Her abstract (O30) Evaluating the effects of exercise on anxiety and depression in 198 older patients with cancer receiving active chemotherapy: data from a randomized controlled trial in the University of Rochester Cancer Center NCI Community Oncology Research Program will be presented on Friday, November 10 at 16:30 in room Warsaw III.

ISHWARIA MOHAN SUBBIAH (US) Cancer remains a disease that disproportionately affects older people. Despite accounting for the greatest proportion of those with cancer, older patients represent a significantly lower proportion of patients included in clinical trials. The care of older adults with cancers calls for a substantial understanding of the intricacies of supportive care and geriatrics, oncology as well as phase I/II clinical trial design. Dr. Subbiah is uniquely qualified for this role, having acquired this essential knowledge through her training at MD Anderson first as a Fellow in the Department of Investigational Cancer Therapeutics (A Phase I Program), then in Medical Oncology in the Division of Cancer Medicine and most recently in Department of Palliative, Rehabilitation, and Integrative Medicine. Dr. Subbiah has a thorough understanding of phase I and II clinical trial design, novel therapeutics including immunotherapy and targeted therapies, fundamentals of medical oncology practice and symptom management. With this robust foundation, she cultivates a clinical practice and research focus on symptom management in all patients with particular emphasis on the older adults.

Her abstract (O28) Comprehensive analysis of immune-related toxicities among older adults treated on novel immunotherapies on phase I clinical trials will be presented on Friday, November 10 at 15:00 in room Warsaw III.

MELISA L. WONG (US) Melisa L. Wong, MD, MAS is an Assistant Professor in the Division of Hematology/Oncology at the University of California, San Francisco (UCSF) in the USA. As a thoracic oncologist, her clinical work and research focus on understanding and improving the care of older adults with lung cancer. Dr. Wong is currently mentored by Chris Miaskowski, RN, PhD, Louise Walter, MD, Arti Hurria, MD, and Alex Smith, MD, MS, MPH to study the impact of chemotherapy, immunotherapy, and targeted therapy on functional status, quality of life, and symptoms in older adults with lung cancer. Her research is supported by the National Institute on Aging Grants for Early Medical/Surgical Specialists’ Transition to Aging Research (GEMSSTAR R03), UCSF Clinical and Translational Science Institute Career Development Award (CTSI KL2), UCSF Claude D. Pepper Older Americans Independence Center Research Education Core Scholar Award, and Conquer Cancer Foundation of ASCO/Vicky Merryman Women Who Conquer Cancer Young Investigator Award. Dr. Wong completed medical school, internal medicine residency, and medical oncology fellowship at UCSF. In addition, she completed advanced research training as an Aging Research T32 Fellow in the UCSF Division of Geriatrics and earned her Master's Degree in Clinical Research in the UCSF Department of Epidemiology and Biostatistics.

Her abstract (O10) Characteristics associated with physical function trajectories in older adults with cancer receiving chemotherapy: a multicenter prospective cohort study will be presented on Thursday, November 9 at 16:30 in room Warsaw IV & V.

SIOG Awards (...continued)


25

Final programme


The SIOG 2017 National Representative of the year Award will be handed out during the SIOG General Assembly on Friday, November 10 at 17:45 in room Warsaw III.

The Paul Calabresi Award will be handed out during the Presidential Session on Saturday, November 11 at 11:30 in room Warsaw IV & V.

SIOG 2017 Paul Calabresi AwardEvery year, the International Society of Geriatric Oncology (SIOG) recognizes a prominent world expert in the Geriatric Oncology field by awarding him/her the Paul Calabresi Award.SIOG members have nominated a peer who has significantly contributed to the advancement of the geriatric oncology field over the past years through the publication of a high impact scientific paper, a significant influence on geriatric oncology policies, a major contribution in the advancement of international collaborations in the field or an outstanding and unconditional support to SIOG.The 2017 Paul Calabresi Award goes to Arti Hurria (US).

SIOG 2017 National Representative of the year AwardThe SIOG National Representative of the year Award recognizes the outstanding contribution to Geriatric Oncology and more particularly to SIOG for the past year. The National Representative of the Year 2017 will be awarded to Theodora Karnakis (BR) for her excellent work and support in the organisation of the 1st SIOG LATAM joint session (in collaboration with the Brazilian Society of Clinical Oncology), to recognize her commitment and loyalty to SIOG and acknowledge her passion about geriatric oncology.

ARTI HURRIACity of Hope Comprehensive Cancer Care, Duarte, CA (US)

Dr. Arti Hurria is a geriatrician and oncologist and is Vice Provost of Clinical Faculty and Director of the Cancer and Aging Research Program at City of Hope. The overall goal of Dr. Hurria’s research program is to improve the care of older adults with cancer. Under Dr. Hurria’s leadership, the Cancer and Aging Research Program has developed and executed over 24 geriatric oncology protocols, enrolling over 3200 participants on studies focused on cancer and aging. Dr. Hurria is principal investigator on 6 NIH-funded grants and has received research support from the Breast Cancer Research Foundation, UniHealth Foundation, and Hearst Foundation. Dr. Hurria leads national and international efforts to improve the care of older adults with cancer. She served on the Institute of Medicine, Committee on “Improving the Quality of Cancer Care: Addressing the Challenges in an Aging Population.” Dr. Hurria serves as the Editor-in-Chief Emeritus for the Journal of Geriatric Oncology (Editor-in-Chief, 2010-2017). She was the recipient of the B.J. Kennedy Award from the American Society of Clinical Oncology, which recognizes scientific excellence in geriatric oncology. In 2016, Dr. Hurria was elected to the Board of Directors for the American Society of Clinical Oncology. Dr. Hurria was the recipient of an endowed chair in geriatric oncology (The George Tsai Geriatric Oncology Chair) in 2017.

THEODORA KARNAKIS (BR)Medical degree from the Pontifical Catholic University of São Paulo (2001); Specialization in Clinical Medicine at Santa Casa of São Paulo medical School (2003-2004); Specialization in Geriatrics at Faculty of Medicine from the University of São Paulo-FMUSP (2005-2006); Geriatrics degree by the Brazilian Society of Geriatrics-SBGG (2007); Post Graduation (Lato Sensu) in Pain and Palliative Care by Hospital Israelita Albert Einstein 2009; Post-graduation (Lato Sensu) in Palliative Care for the Palliun- Oxford University UK (2010-2011); Post Graduation (Stricto Sensu) PhD in medical sciences at the University of São Paulo - FMUSP (2015);Since 2007 she has started her interest in elderly cancer patients; Was coordinator and founder of the Geriatric Oncology team at Hospital Israelita Albert Einstein (HIAE) In (2010-2013). Since then she has been the author of the first Geriatric Oncology Book in Brazil and coordinator of two geriatric oncology national symposiums.Currently, she is a coordinating physician of the Geriatric Oncology service at the Cancer Institute of the State of São Paulo/University of São Paulo (ICESP / FMUSP) and at Sírio libanês Hospital, SP, Brazil .Her priority is developing geriatric oncology research in Brazil and promoting interest and education for young medical oncologists and geriatricians in this area.National representative of the International Society of Geriatric Oncology (SIOG) since 2012.


26

Final programme


Programme at a glance17th Annual Conference of the International Society of Geriatric Oncology

“From research to pratice: incorporating geriatic oncology into patient care”

Thursday Friday SaturdayNovember 9, 2017 November 10, 2017 November 11, 2017Warsaw IV&V Warsaw III Warsaw IV&V Warsaw III Warsaw IV&V Warsaw III

07:45

Speakers preview centre - 07:30-19:00

Registration - 07:30-18:30




08:0008:00-09:00

Plenary session: Hot topics in geriatric oncology

08:15

08:30 08:30-09:00Opening address

08:30-09:30Plenary session:

Geriatric Oncology: From research to practice: incorporating geriatric oncology

into patient care

08:45

09:0009:00-10:00

Plenary session:Advancements in the field of

geriatric oncology

09:00-10:00TRACK 1

Managing older patients with headand neck cancer

09:00-10:00TRACK 2

Multidisciplinary care in the haematology

clinic

09:15

09:30

Exhibition - 09:30-17:30

9:30-11:00TRACK 1

Liver cancerin the elderly

9:30-11:00TRACK 3

Therapy-related toxicities: unique challenges and

the importance of communication

09:45


10:00 10:00-10:30Coffee break - Poster viewing

10:00-10:30Coffee break - Poster viewing10:15

10:30

10:30-12:00TRACK 1

Optimal management of localized rectal cancer

in older patients

10:30-12:00TRACK 3

Optimising medication management

in supportive care

10:30-11:30Industry sponsored satellite session

10:45

11:00 11:00-11:30Coffee break - Poster viewing11:15

11:30

11:30-13:00TRACK 5

Oral abstractsession 2

11:30-13:00TRACK 1

Oral abstractsession

11:30-12:30SIOG Presidential session

and SIOG awards

11:45

12:00

Lunch break &Poster view

ing

12:1512:15-13:15

Young SIOG Research session

12:30


ing

12:4512:45-13:45

Young SIOG General assembly

12:45-13:45SIOG NR

and Membership committee meeting

13:00


ing

13:15

13:3013:30-14:30

TRACK 5 Oral abstract session 1

13:30-14:30TRACK 4

Patient-centered surgical care of the older cancer patient

13:45

14:00

14:00-15:30TRACK 5

Geriatric assessment in practice

14:00-15:30TRACK 4

Emerging diagnostics and therapeutics

14:15

14:30 14:30-15:30TRACK 5

Multicultural perspective

on cancer care

14:30-15:30TRACK 4

Oral abstract session

14:45 14:45-15:45TRACK 1

Treatment of advanced prostate cancer

in the elderly

14:45-15:45TRACK 2


15:00

15:15

15:30 15:30-16:00Coffee break - Poster viewing

15:30-16:45SIOG Guidelines update 2017

15:45 15:45-16:15Coffee break - Poster viewing16:00 16:00-17:00

TRACK 3Exercise for managing

side effects among geriatric oncology patients

16:00-17:00TRACK 5

Mini multidisciplinary team (MDT)

case discussion

16:15

16:15-17:45TRACK 3


16:15-17:45TRACK 5

NAH & EONS joint session

16:30

16:45

17:00

17:15

17:15-18:30SIOG General Assembly

17:30

17:45

18:00

18:00-19:00Poster welcome reception

18:15

18:30

18:45

19:00

19:15

19:30

SIOG 2017 Networking Dinner 19:30-22:30

19:45

20:00

20:15

20:30

20:45

21:00

21:15

21:30

21:45

22:00

22:15

n Track 1: Solid tumours in the elderlyand basic sciencen Track 2: Haem malignancies in the elderly and basic sciencen Track 3: Supportive and palliative care n Track 4: Modern diagnostics and therapeutic areasn Track 5: Geriatric assessment, nursing/allied health and patient care




27

Final programme


DAY 1 - Thursday, November 9, 2017Warsaw IV & V

08:30-09:00 Opening address

08:30-08:40 Opening address by SIOG President Stuart Lichtman (US)08:40-08:50 Scientific programme overview by the Chair of SIOG 2017 Annual Conference Demetris Papamichael (CY)08:50-09:00 Welcome address by National Host Agnieszka Jagiełło-Gruszfeld (PL)

Warsaw IV & V

09:00-10:00 Plenary session: Advancements in the field of geriatric oncology Chairs: Siri Rostoft (NO) and Stuart Lichtman (US)

09:00-09:12 Advancements in the management of metastatic breast cancer Hans Wildiers (BE)09:12-09:24 Updates in geriatrics Marije Hamaker (NL)09:24-09:36 Advancements in the management of lung cancer Lore Decoster (BE)09:36-09:48 Advances in gynaecologic oncology William Tew (US)09:48-10:00 Discussion and questions

10:00-10:30 Coffee break - Poster viewing

Warsaw IV & V

10:30-12:00 Optimal management of localized rectal cancer in older patients Chairs: Rob Glynne-Jones (GB)and Krzysztof Bujko (PL)

10:30-10:40 Case presentation Rob Glynne-Jones (GB)10:40-10:55 Surgical aspect Harm Rutten (NL)10:55-11:10 Adjuvant therapy and toxicity issues Demetris Papamichael (CY)11:10-11:25 Radiation Krzysztof Bujko (PL)11:25-11:40 Long-term consequences and survivorship after rectal cancer diagnosis Rob Glynne-Jones (GB)11:40-12:00 Discussion and questions

Warsaw III

10:30-12:00 Optimising medication management in supportive care Chairs: Carla Ripamonti (IT) and Ronald Maggiore (US)10:30-10:40 Case presentation Kah Poh Loh (US)10:40-10:55 Antipsychotics: between prevention of nausea and vomiting, Rosa Liperoti (IT) treatment of behavioural disturbances and risk of adverse events10:55-11:10 Deprescribing Tomasz Grodzicki (PL)11:10-11:25 Highlights in the management of pain in elderly cancer patients Walter Gianni (IT)11:25-11:40 What is on the horizon: recent data on the use of technology in drug management Ronald Maggiore (US)11:40-12:00 Discussion and questions

12:00-13:30 Lunch break - Poster viewing and exhibition

Warsaw III

12:15-13:15 Young SIOG Research session

This new session will include 3 research proposals that will be presented by young SIOG members, after which a panel of experienced researchers (Martine Extermann (US) & Etienne Brain (FR)) will comment on the research strategy, methodology and chances and opportunities. We will have a plenary discussion on how your proposal may be improved and carried out.

12:15-12:25 Research proposal 1: Predicting treatment morbidity from sorafenib in elderly patients Sukeshi Patel Arora (US) with advanced hepatocellular carcinoma (HCC) with varying liver dysfunction12:25-12:35 Panel discussion Martine Extermann (US) and Etienne Brain (FR)12:35-12:45 Research proposal 2: Peer-questioned assessment of premorbid geriatric function Nina Rosa Neuendorff (DE) in patients with AML and its impact on survival and treatment tolerability12:45-12:55 Panel discussion Martine Extermann (US) and Etienne Brain (FR)12:55-13:05 Research proposal 3: Oncologists’ perspectives of the survivorship care plans Jessica L. Krok (US) for older breast cancer survivors13:05-13:15 Panel discussion Martine Extermann (US) and Etienne Brain (FR)

n SIOG sessions n Plenary sessions n Track 1 n Track 2 n Track 3 n Track 4 n Track 5 n Industry sponsored satellite sessions


NEW I Q&A and session rating toolEnter this link into your browserwww.siog2017.cnf.ioor scan the QR code

28

Final programme


Warsaw IV & V

13:30-14:30 Oral abstract session 1: Geriatric assessment, Chairs: Siri Rostoft (NO) and Petra Stolz-Baskett (NZ) nursing/allied health and patient care

13:30-13:45 O01 - Older cancer patients’ perception of their preoperative activity level compared Armin Shahrokni (US) to the people of their age strongly correlates with their frailty status & overall survival

13:45-14:00 O02 - A novel geriatric assessment tool that predicts postoperative surgical Yaoyao Pollock (US) and geriatric complications in older adults with cancer

14:00-14:15 O03 - The effect of live music on postoperative pain in elderly patients Hanneke Van der Wal-Huisman (NL)

14:15-14:30 O04 - The care program: occupational Mackenzi Pergolotti (US) and physical therapy for older adults with cancer SIOG Nursing & Allied Health Award finalist

Warsaw III

13:30-14:30 Patient-centred surgical care of the older cancer patient Chairs: Michael Jaklitsch (US) and Barbara Van Leeuwen (NL)

13:30-13:40 Case presentation Michael Jaklitsch (US)

13:40-13:53 Pre-operative assessment Michael Jaklitsch (US)

13:53-14:06 Electronic Rapid Fitness Assessment: conception, development and potential uses Armin Shahrokni (US)

14:06-14:19 Optimising post-operative care Barbara Van Leeuwen (NL)

14:19-14:30 Discussion and questions

Warsaw IV & V

14:45-15:45 Educational session: Update of the treatment Chairs: Nicolas Mottet (FR) and Eleni Efstathiou (GR/US) of prostate cancer in the elderly

14:45-15:00 Urological aspects and application of SIOG guidelines Nicolas Mottet (FR)

15:00-15:15 Consensus of the Advanced Prostate Cancer Conference 2017 (St. Gallen, CH) Iwona Skoneczna (PL)

15:15-15:30 Presentation of the outstanding phase III trials: ASCO 2017 (Latitude and Stampede) Eleni Efstathiou (GR/US)

15:30-15:45 Case discussion Shabbir Alibhai (CA)

Warsaw III

14:45-15:45 Oral abstract session: Haem malignancies in the elderly Chairs: Reinhard Stauder (AT) and Kah Poh Loh (US) and basic science

14:45-15:00 O05 - Survival of AML patients aged 70 and older: Martine Extermann (US) Modelling from data obtained in more than 13,000 patients

15:00-15:15 O06 - Major impact of Mild Cognitive Impairment (MCI) and inflammatory status Stéphanie Dubruille (BE) in older patients receiving chemotherapy for haematological malignancies

15:15-15:30 O07 - A link between psoas muscle area and outcomes in elderly patients Agata Schlesinger (IL) with diffuse large B-cell lymphoma treated with R-CHOP

15:30-15:45 O08 - Transcription factors (BACH2 and PRDM1) and checkpoint inhibitors expression Dominique Bron (BE) in T-lymphocytes from chronic lymphocytic leukemia patients and age-matched healthy donors

15:45-16:15 Coffee break - Poster viewing and exhibition

Warsaw IV & V

16:15-17:45 Oral abstract session: Supportive and palliative care Chairs: Adam Pluzanski (PL) and Shane O'Hanlon (GB)

16:15-16:30 O09 - Factors associated with advance directives completion Enrique Soto Perez de Celis (MX & US) among older adults with cancer

16:30-16:45 O10 - Characteristics associated with physical function Melisa L Wong (US) - SIOG Young Investigator Award finalist trajectories in older adults with cancer receiving chemotherapy: a multicenter prospective cohort study

16:45-17:00 O11 - Older adults’ use of cancer-related internet Kristen R Haase (CA) - SIOG Nursing & Allied Health Award finalist information: conclusions and future directions from a qualitative study

17:00-17:15 O12 - Health-related quality of life as a predictor of 10-year mortality in older patients Clark Dumontier (US) with early stage breast cancer

17:15-17:30 O13 - Fatigue during oncologic treatments in elderly versus young patients: Claire Falandry (FR) a call for SIOG recommendations



DAY 1 - Thursday, November 9, 2017



29

Final programme


Warsaw III

16:15-17:45 SIOG Nursing and Allied Health Interest Group & EONS Joint session: Chairs: Martine Puts (CA) and Petra Stolz-Baskett (NZ) Caring for older patients with cancer: experiences, assessment and management

16:15-16:35 Caring for older patients with cancer with a patient-centred approach: Andreas Charalambous (CY) does it impact health status, quality nursing care and trust in nurses?

16:35-16:55 Smart phone real time symptom assessment and management Lisa McCann (GB)

16:55-17:15 Falls in older patients with cancer: assessment and management Schroder Sattar (CA)

17:15-17:35 Dignity in care: developing, adapting and implementing the dignity care intervention (DCI) Ulrika Östlund (SE) in community care for older persons in palliative phase


18:00-19:00 Poster welcome reception





30

Final programme


DAY 2 - Friday, November 10, 2017 Warsaw IV & V

08:30-09:30 Plenary session - From research to practice: Chairs: Shabbir Alibhai (CA) and Stuart Lichtman (US) incorporating geriatric oncology into patient care

08:30-08:42 Modernising clinical trials Stuart Lichtman (US)

08:42-08:54 How to use clinical trial data in everyday practice Martine Extermann (US)

08:54-09:06 Patient reported outcomes Barbara Van Leeuwen (NL)

09:06-09:18 Conducting RCTs: Intervention study of frail older patients with cancer in France Pierre Soubeyran (FR)


Warsaw IV & V

09:30-11:00 Educational session: Liver cancer in the elderly Chairs: Daniel Anaya (US) and Sarah Hoffe (US)

09:30-09:50 Liver cancer: a common and reversible cause of mortality in older patients Lodovico Balducci (US)

09:50-10:10 Surgical treatment of primary and secondary liver cancer Daniel Anaya (US)

10:10-10:30 A radiation oncology perspective Jessica Frakes (US)

10:30-10:50 Interventional radiology and the management of liver cancer Junsung Choi (US)

10:50-11:00 Conclusions Sarah Hoffe (US)

Warsaw III

09:30-11:00 Therapy-related toxicities: Chairs: Adam Pluzanski (PL) and Karis Kin-Fong Cheng (SG) unique challenges and the importance of communication

09:30-09:40 Case presentation Supriya Mohile (US)

09:40-09:55 Cognitive impairment as a treatment induced toxicity Katarzyna Broczek (PL)

09:55-10:10 Adherence to antiemetic treatment Adam Pluzanski (PL)

10:10-10:25 Diarrhoea during oncological treatments Domenico La Carpia (IT)

10:25-10:40 Communication on toxicity management: how do we get the message across Karis Kin-Fong Cheng (SG)


11:00-11:30 Young SIOG Poster discussion

Check out the best prospective and innovative studies for each of our five SIOG 2017 scientific tracks. The Young SIOG Poster discussion is led by Arti Hurria (US) and Martine Extermann (US). Join us in the back of the poster hall for this discussion.


Warsaw IV & V

11:30-13:00 Oral abstract session 2: Geriatric assessment, Philippe Caillet (FR) and Katarzyna Broczek (PL) nursing/allied health and patient care

11:30-11:45 O20 - Including patient preferences and geriatric assessment Suzanne Festen (NL) in the everyday decision making process

11:45-12:00 O21 - Opening up the black box of CGA in geriatric oncology clinic: Shabbir Alibhai (CA) understanding enhancements to care beyond treatment-decision making

12:00-12:15 O22 - Impact of a specific multidisciplinary geriatric Ramona Moor (BE) oncology clinical pathway on the number SIOG Nursing & Allied Health Award finalist and types of implemented geriatric interventions

12:15-12:30 O23 - The relationships between geriatric impairments, symptom severity, Supriya Mohile (US) and quality of life in 342 older adults with advanced cancer: a University of Rochester NCI Community Oncology Research Program (UR NCORP) multisite trial

12:30-12:45 O24 - The impact of geriatric assessment measures on caregiver emotional health: Supriya Mohile (US) data from a multicenter Geriatric Assessment (GA) study in the University of Rochester NCI Community Oncology Research Program (UR NCORP) network

12:45-13:00 O25 - Unmet social support needs among older adults with cancer Grant Williams (US)




31

Final programme


DAY 2 - Friday, November 10, 2017Warsaw III

11:30-13:00 Oral abstract session: Solid tumours in the elderly Chairs: William Tew (US) and Agnieszka Jagiełło-Gruszfeld (PL) and basic science

11:30-11:45 O14 - Bevacizumab chemotherapy versus chemotherapy alone in older patients Thomas Aparicio (FR) with untreated metastatic colorectal cancer: a randomized phase II trial - Prodige 20 study results11:45-12:00 O15 - Associations of pre-chemotherapy inflammation with post-chemotherapy frailty Nikesha Gilmore (US) in patients with breast cancer aged 50+: longitudinal data from the University of Rochester NCI Community Oncology Research Program (UR NCORP) Network12:00-12:15 O16 - NORDIC9: a Nordic randomized phase II trial exploring treatment Stine Braendegaard Winther (DK) strategies of older patients with metastatic colorectal cancer; results of a pre-planned safety analysis12:15-12:30 O17 - Toward personalizing care for older men with MCRPC (TOPCOP): Henriette Breunis (CA) the effect on physical function from treatment for MCRPC12:30-12:45 O18 - Factors associated with the inflammatory response to surgery in elderly oncological patients Matthijs Plas (NL)12:45-13:00 O19 - Radiotherapy for elderly patients with glioblastoma multiform, Eleanor Smith (GB) patient outcomes in routine clinical practice


Warsaw IV & V

14:30-15:30 Multicultural perspective on cancer care Chairs: Gouri Shankar Bhattacharyya (IN) and Etienne Brain (FR)

14:30-14:42 Geriatric oncology in resource constrained countries Gouri Shankar Bhattacharyya (IN) 14:42-14:54 Population aging in Latin America and its impact on public health Theodora Karnakis (BR)14:54-15:06 Clinical research across countries and culture: how to take into account diversity? Etienne Brain (FR)15:06-15:18 Supportive care: questions and suggested solutions from the Polish perspective Adam Pluzanski (PL)15:18-15:30 Discussion and questions

Warsaw III

14:30-15:30 Oral abstract session: Modern diagnostics Chairs: Lodovico Balducci (US) and Fábio Gomes (PT/GB) and therapeutic areas

14:30-14:45 O26 - Feasibility of enrolling vulnerable older adults with cancer Ronald Maggiore (US) in a geriatric assessment model of care cluster randomized trial14:45-15:00 O27 - Genetic profile and clinical characteristics of older women Yanin Chavarri-Guerra (MX) with breast cancer in the clinical cancer genomics community research network15:00-15:15 O28- Comprehensive analysis of immune-related Ishwaria Subbiah (US) - SIOG Young Investigator Award finalist toxicities among older adults treated on novel immunotherapies on phase I clinical trials15:15-15:30 O29 - Tolerability and outcomes of radiation therapy for breast cancer Kim Cao (FR) in older women: a retrospective study in 817 patients


Warsaw IV & V

16:00-17:00 Exercise for managing side effects Chairs: Karen Mustian (US) and Katarzyna Broczek (PL) among geriatric oncology patients

16:00-16:15 Yoga for managing insomnia, fatigue and quality of life among geriatric cancer survivors Karen Mustian (US)16:15-16:30 Improved functional capacity and reduced fatigue: the impact of exercise for patients with lung cancer Morten Quist (DK)16:30-16:45 O30 - Evaluating the effects of exercise on anxiety Kah Poh Loh (US) and depression in 198 older patients with cancer receiving active chemotherapy: SIOG Young Investigator Award finalist data from a randomized controlled trial in the University of Rochester Cancer Center NCI Community Oncology Research Program16:45-17:00 Discussion and questions

Warsaw III

16:00-17:00 Mini multidisciplinary team (MDT) case discussion Chairs: Shane O’Hanlon (GB) and Martine Extermann (US)

Interesting cases submitted by SIOG 2017 attendees will be discussed in this session Session objectives: 1. To illustrate how lessons can be learned from reflecting on MDT decisions 2. To demonstrate how a truly diverse MDT membership can be advantageous when dealing with challenging cases 3. To show the depth of knowledge and experience of SIOG's audience 4. To encourage MDT members to “think outside the box” and reflect on how the team can improve its performance

Warsaw III

17:15-18:45 SIOG General assembly

For SIOG members only



32

Final programme


DAY 3 - Saturday, November 11, 2017Warsaw IV & V

08:00-09:00 Plenary session: Hot topics in geriatric oncology Chairs: Beatriz Korc-Grodzicki (US) and Cindy Kenis (BE)

08:00-08:12 Role of the geriatrician/primary care/NAH provider during treatment delivery Martine Puts (CA)

08:12-08:24 Cardiotoxicity in oncology practice Christopher Plummer (GB)

08:24-08:36 Role of geriatrician/primary care/community care during survivorship Beatriz Korc-Grodzicki (US)

08:36-08:48 Cognitive functions in survivors Carla Ripamonti (IT)


Warsaw IV & V

09:00-10:00 Managing older patients with head and neck cancer Chairs: Paolo Bossi (IT) and Charles Kelly (GB)

09:00-09:12 Chemo radiation in elderly patients with head and neck cancer: Muhammad Shahid Iqbal (GB) patient selection, efficacy and toxicity

09:12-09:24 Geriatric assessment of the older head and neck patients Ronald Maggiore (US)

09:24-09:36 Multidisciplinary approach to head and neck including newer treatment modalities Paolo Bossi (IT)

09:36-09:48 Quality of life and survivorship issues in older patients with head and neck cancer Charles Kelly (GB)


Warsaw III

09:00-10:00 Multidisciplinary care in the haematology clinic Chairs: Pierre Soubeyran (FR) and Valentin Goede (DE)

09:00-09:14 Geriatric haematology clinic: oncologist’s perspective Reinhard Stauder (AT)

09:14-09:28 Geriatric haematology clinic: geriatrician's perspective Jarred Rosenberg (CA)

09:28-09:42 Geriatric haematology clinic: nurse's perspective Diane Tilmant-Tatischeff (FR)

09:42-09:52 Conclusion and remarks Pierre Soubeyran (FR) and Valentin Goede (DE)



Warsaw IV & V

10:30-11:30 Industry sponsored satellite session

Further information available on page 43.

Warsaw IV & V

11:30-12:30 SIOG presidential session and SIOG 2017 awards Chair: Stuart Lichtman (US)

11:30-11:40 Presidential address Stuart Lichtman (US)

11:40-11:45 SIOG Lifetime achievement award Lodovico Balducci (US)

11:45-11:55 SIOG 2017 Calabresi award presentation “It’s a small world after all” Arti Hurria (US)

11:55-12:05 SIOG 2017 Nursing & Allied Health Investigator award Stuart Lichtman (US) and Hans Wildiers (BE)

12:05-12:15 SIOG 2017 Young Investigator award Stuart Lichtman (US) and Hans Wildiers (BE)

12:15-12:25 SIOG 2017 Best Poster award Stuart Lichtman (US) and Etienne Brain (FR)

12:25-12:30 SIOG 2018 Annual Conference announcement Stuart Lichtman (US)


Warsaw IV & V

12:45-13:45 Young SIOG General assembly Chairs: Nienke de Glas (NL) and Mandy Kiderlen (NL)

Young SIOG is a SIOG Interest Group that reaches out to all young clinicians and researchers who work in all disciplines that deal with cancer in older patients. In this Young SIOG session, ongoing and future projects of the group will be discussed. Members will get the opportunity to give feedback and to bring new ideas to the group.

Warsaw III

12:45-13:45 SIOG Membership and National Representative Committee meeting

For SIOG National Representatives only




33

Final programme


DAY 3 - Saturday, November 11, 2017Warsaw IV & V

14:00-15:30 Geriatric assessment in practice Chairs: Martine Puts (CA) and Hans Wildiers (BE)

14:00-14:20 Evidences of multidisciplinary interventions in frail patients in the context of geriatric oncology Philippe Caillet (FR)

14:20-14:40 Implementation of geriatric interventions in the management of elderly patients with cancer Hans Wildiers (BE)

14:40-15:00 Recognising and effectively preventing and managing delirium in older inpatient Marije Hamaker (NL) with cancer with palliative care needs

15:00-15:20 Musculoskeletal aging, sarcopenia and cancer Giuseppe Colloca (IT)


Warsaw III

14:00-15:30 Emerging diagnostics and therapeutics Chairs: Shabbir Alibhai (CA) and Carlos Gomez-Roca (FR)

14:00-14:15 Cancer screening in the elderly and its limits Shabbir Alibhai (CA)

14:15-14:30 New technologies in geriatric oncology care Armin Shahrokni (US)

14:30-14:45 Precision medicine in the elderly: are we there yet? Carlos Gomez-Roca (FR)

14:45-15:00 The role of immunotherapy in the elderly Alastair Greystoke (GB)

15:00-15:15 New techniques in radiotherapy Charles Kelly (GB)


Warsaw IV & V

15:30-16:45 SIOG Guidelines update 2017 Chairs: Tanya Wildes (US) and Kwok-Leung Cheung (GB)

15:30-15:50 Adherence to oral cancer therapy in older patients Tanya Wildes (US)

15:50-16:10 Quality of life in older cancer patients Fábio Gomes (PT/GB)

16:10-16:30 Impact of nutrition in the management outcomes of older adults with gastrointestinal cancers Federico Bozetti (IT)




34

Final programme


TRACK 1: SOLID TUMOURS IN THE ELDERLY AND BASIC SCIENCE

Abstract final identifier

Presenting author ABSTRACT TITLE

P002Nicolò Matteo Luca Battisti

OUTCOMES OF SYSTEMIC THERAPY FOR ADVANCED TRIPLE-NEGATIVE BREAST CANCER IN PATIENTS AGED 65 AND OLDER: A REAL-WORLD EXPERIENCE.

P003 Kyara Bergstrom PRIMARY ENDOCRINE THERAPY IN ELDERLY BREAST CANCER PATIENTS FROM A SINGLE UNIT IN SOUTH AFRICA:

P004 Manuela Bernardo EARLY BREAST CANCER IN ELDERLY WOMEN - MORE WEAKNESSES THAN STRENGHTS - 11 YEAR RETROSPECTIVE ANALYSIS

P005Alexandrede Nonneville

SAFETY AND EFFICACY OF ERIBULIN FOR “REAL-WORLD” ELDERLY METASTATIC BREAST CANCER PATIENTS

P007 Agnieszka Gruzfeld NEOADJUVANT TREATMENT WITH LETROZOLE IN ELDERLY BREAST CANCER PATIENTS - OBSERVATIONAL STUDY

P008 Theodora Karnakis DOES BREAST CANCER SCREENING COULD IMPACT IN OVERALL SURVIVAL IN BREAST CANCER PATIENT OLDER THAN 80?

P010 Marcin MaczkiewiczTREATMENT RELATED TOXICITIES IN ELDERLY VERSUS YOUNGER CONTROLS WITH HER2 POSITIVE METASTATIC BREAST CANCER PATIENTS TREATED WITH CAPECITABINE AND LAPATINIB - ANALYSIS OF LONGITUDINAL DATA FROM POPULATIONAL REGISTRY.

P011 Kwok-Leung Cheung CYCLIN E IN EARLY OPERABLE PRIMARY BREAST CANCER IN OLDER WOMEN – ANALYSIS OF CLINICAL OUTCOME AND RELATIONS WITH BIOMARKERS

P012Ewa Franciszka Szu-macher

SENIOR WOMEN BREAST CANCER CLINIC AT SUNNYBROOK ODETTE CANCER CENTRE AN INTERPROFESSIONAL GERIATRIC ONCOLOGY INITIATIVE - 2 YEAR EXPERIENCE

P013 Sukeshi Patel Arora PHASE 1 CLINICAL TRIALS IN REFRACTORY COLORECTAL CANCER (CRC): DO OLDER ADULT PATIENTS BENEFIT?

P014 Sukeshi Patel Arora COMPARATIVE EFFICACY AND SAFETY OF SORAFENIB IN ELDERLY VERSUS NON-ELDERLY PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC) WITH VARYING LIVER DYSFUNCTION.

P016 Lynda Corrigan INFLUENCE OF OLDER AGE ON TREATMENT DECISIONS AND OUTCOMES FOR RECTAL CANCER: A RETROSPECTIVE STUDY.

P017 Floris A de JongLIPOSOMAL IRINOTECAN (NAL-IRI) PLUS 5-FLUOROURACIL AND LEUCOVORIN IN PATIENTS WITH METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA (MPDAC) PREVIOUSLY TREATED WITH GEMCITABINE-BASED THERAPY: DATA FROM ELDERLY PATIENTS IN THE PIVOTAL PHASE 3 NAPOLI-1 STUDY

Scientific poster displayAbstract posters will be displayed in the poster area within the exhibition area during the whole duration of the conference. Presenting authors are kindly requested to be present at their poster for presentation on:

Thursday, November 9, 2017 10:00-10:30 / 12:30-13:15 / 15:45-16:15 and 18:00 for the Poster Welcome Reception

Friday, November 10, 2017 11:00-11:30 / 13:15-14:00 and 15:30-16:00

Saturday, November 11, 2017 10:00-10:30 and 12:30-13:15

Young SIOG Poster discussionFriday, November 10, 2017 - 11:00-11:30 - Poster area

Check out the best prospective and innovative studies for each of our five SIOG 2017 scientific tracks (P030, P038, P043, P067, P104 – highlighted with the Young SIOG logo on the following poster listing). A poster discussion with the authors is led by Arti Hurria and Martine Extermann. Meeting point is in the back of the poster hall.

YOUNGSIOG


35

Final programme


P018 Leonor Fernandes ADJUVANT CHEMOTHERAPY IN SENIOR PATIENTS WITH STAGE II CRC - YES OR NO?

P019 Alexandra Lewis OUTCOMES IN PATIENTS AGED ≥80 YEARS WITH HEPATOPANCREATICOBILIARY (HPB) MALIGNANCIES

P020 Sonia Jimenez Mola COLON CANCER AND HIP FRACTURE : CASE REPORT

P021 Toshikazu MoriwakiIMPACT OF AGE ON EFFICACY AND SAFETY IN ELDERLY PATIENTS WITH METASTATIC COLORECTAL CANCER WHO RECEIVED URACIL-TEGAFUL AND ORAL LEUCOVORIN COMBINED WITH BEVACIZUMAB: A POST-HOC ANALYSIS OF J-BLUE STUDY.

P022 Gemma Soler COLORECTAL SURGERY IN THE ELDERLY. DOES THE EXTREME AGE DETERMINE THE ODDS RATIO OF COMPLICATIONS?

P025 Alexandre Hamelin THE OUTCOME OF COMBINED-MODALITY THERAPY FOR LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER: A RETROSPECTIVE REVIEW OF PATIENTS TREATED AT CHARLES LEMOYNE HOSPITAL FROM 2011 TO 2016.

P026 Andrea Bellieni SKIN CANCER EPIDEMICS IN THE ELDERLY AS AN EMERGING ISSUE IN GERIATRIC ONCOLOGY

P028ElisabethCastel-Kremer

ONCOLOGIC AND GERIATRIC JOINT CARE OF ELDERLY PATIENTS WITH NEUROENDOCRINE TUMORS : OBSERVATIONAL STUDY IN REFERENCE CENTER

P029Camilla Maria Guimarães Augusto

QUALITY OF LIFE ASSESSMENT IN ELDERLY PATIENTS WITH PROSTATE CANCER DURING SIX MONTHS OF TREATMENT.

P030 Henriette Breunis THE EFFECT OF TREATMENT WITH CHEMOTHERAPY OR ENZALUTAMIDE ON COGNITIVE FUNCTION IN OLDER ADULTS WITH METASTATIC CASTRATE-RESISTANT PROSTATE CANCER.

P032 Sonia Jimenez Mola HIP FRACTURE AND PROSTATE CANCER

TRACK 2: HAEM MALIGNANCIES IN THE ELDERLY AND BASIC SCIENCE



P035 Raul Cordoba COMPREHENSIVE GERIATRIC ASSESSMENT IN ROUTINE DAILY CLINICAL PRACTICE IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES AGED 70 OR OVER

P037 Masaru Shibata PREDICTABILITY OF GERIATRIC ASSESSMENT IN ELDERLY PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA

P038 Jean BaptisteFargeas

HEMATO-GERIATRIC PATHWAY OF PATIENTS OLDER THAN 65 WITH MYELOMA: PREDICTIVE VALUE OF GERIATRIC ASSESSMENT ON THE OCCURRENCE OF CHEMOTHERAPY INTERCURE EVENTS.

P039 Jelena Hajder IADL EVALUATION IS DEPENDENT ON SLUMS SCORE IN ELDERLY PATIENTS DIAGNOSED WITH HEMATOLOGIC MALGNANCY

P040 Jessica L. Krok INCIDENCE AND SURVIVAL OF HEMATOLOGICAL CANCERS AMONG ADULTS AGED ≥75 YEARS

P041 Morgani Rodrigues THE ROLE OF GERIATRIC ASSESSMENT IN ELDERLY PATIENTS SUBMITTED TO ALLOGENEIC BONE MARROW TRANSPLANT: A RETROSPECTIVE ANALYSIS

P042 Morgani Rodrigues THE COMPREHENSIVE GERIATRIC ASSESSMENT IN ELDERLY PATIENTS SUBMITTED TO AUTOLOGOUS BONE MARROW TRANSPLANT: A RETROSPECTIVE ANALYSIS

YOUNGSIOG

YOUNGSIOG


36

Final programme


YOUNGSIOG

YOUNGSIOG

TRACK 3: SUPPORTIVE AND PALLIATIVE CARE



P043 Domenico La Carpia COGNITIVE DECLINE AND FUNCTIONAL STATUS IN ELDERLY CANCER SURVIVORS FROM NON HODGKIN LYMPHOMA

P044 Simona Mihutiu CHEMO BRAIN OR AGED BRAIN? A PROSPECTIVE RESEARCH ON ELDERLY CANCER PATIENTS BEFORE AND AFTER CHEMOTHERAPY

P046 Tanya Wildes ADAPTATION OF THE FALL PREVENTION INTERVENTION STEPPING ON FOR OLDER ADULTS WITH CANCER

P047Maria Teresa Antonio Rebollo

FACTORS INFLUENCING MORTALITY IN ELDERLY PATIENTS WITH SOLID TUMOURS WITH BLOODSTREAM INFECTION.

P048Maria Teresa Antonio Rebollo

BLOODSTREAM INFECTIONS IN PATIENTS WITH SOLID CANCER: DIFFERENCES BETWEEN YOUNG AND ELDERLY PATIENTS

P049 Rana Bahij THE IMPACT ON SURVIVAL COMPARING TREATED PATIENTS WITH SCLC HAVING A PS 3-4 WITH UNTREATED PATIENTS

P051 Valentin Goede MULTICOMPONENT INTERVENTION FOR MANAGEMENT OF GERIATRIC IMPAIRMENTS IN OLDER ADULTS WITH CANCER: CASE SERIES FROM A NEWLY FOUNDED ONCOGERIATRIC UNIT

P052 Mohamed Hablas PALLIATIVE CARE IN EGYPT: THE EXPERIENCE OF THE GHARBIA CANCER SOCIETY.

P055 Elena Allocca QUALITY OF LIFE AND PATIENTS REPORTED OUTCOMES IN ELDERLY PATIENTS WITH BREAST CANCER

P056Karis Kin-Fong Cheng

A SYSTEMATIC REVIEW OF DEPRESSION IN ELDERLY PATIENTS WITH CANCER

P058 Andrea Bellieni SARCOPENIA, DECONDITIONING AND CACHEXIA IN ELDERLY PATIENT WITH CANCER: A MONOCENTRIC STUDY

P059Karis Kin-Fong Cheng

PREVALENCE AND OUTCOMES OF MALNUTRITION IN OLDER CANCER PATIENTS: A SYSTEMATIC REVIEW

TRACK 4: MODERN DIAGNOSTICS AND THERAPEUTIC AREAS



P060 Idoia Morilla EFFICACY OF ERIBULIN IN HER2-NEGATIVE ADVANCED BREAST CANCER. COMPARATIVE ANALYSIS: OLDER PATIENTS VERSUS YOUNGER ONES

P061 In Gyu Hwang ASSOCIATED FACTORS AND CLINICAL OUTCOMES OF CHEMOTHERAPY DOSE REDUCTION AT FIRST CYCLE IN ELDERLY PATIENTS WITH SOLID TUMORS

P062 Claire Falandry CHANGES IN THE UTILIZATION OF COMPREHENSIVE GERIATRIC ASSESSMENT IN CLINICAL TRIALS FOR ELDERLY CANCER PATIENTS OVER TIME

P063 Heike Schmidt MEASUREMENT OF HEALTH RELATED QUALITY OF LIFE IN OLDER CANCER PATIENTS IN STUDIES

P064BozenaCybulska-Stopa

IMMUNE CHECKPOINT INHIBITORS THERAPY IN ELDERLY (≥70 YEAR-OLD) PATIENTS WITH METASTATIC MELANOMA.

P065 Won Sup Yoon WHICH FACTORS ARE RELATED WITH INCOMPLETE RADIOTHERAPY OF PRIMARY TUMORS IN ELDERLY PATIENTS?

P066 Theodora Karnakis CORRELATION OF PREOPERATIVE FRAILTY AND FUNCTIONALITY CRITERIA AS PREDICTORS OF POSTOPERATIVE MORTALITY IN THE ELDERLY PATIENTS 80 YEARS AND OLDER UNDERGOING ONCOLOGIC SURGERY.

P067 Esteban Td Souwer A PREHABILITATION AND REHABILITATION PROGRAM FOR ELDERLY COLORECTAL CANCER PATIENTS


37

Final programme


TRACK 5: GERIATRIC ASSESSMENT, NURSING/ALLIED HEALTH AND PATIENT CARE



P068Gouri Shankar Bhat-tacharyya

EFFECT OF HEALTH LITERACY ON ADHERENCE OF ORAL CAPECITABINE IN GERIATRIC POPULATION.

P069 Jean-Yves Niemier MISCONCEPTIONS AND GOOD PRACTICES IN GERIATRIC ONCOLOGY : MEDICAL AND LEGAL ARGUMENTS TO FIGHT TEN FALSE IDEAS

P070 Jee Hyun Kim IMPACT OF SOCIOECONOMIC DISPARITIES ON HEALTH CARE UTILIZATION AND OVERALL MORTALITY IN ELDERLY CANCER PATIENTS: A NATION-WIDE POPULATION-BASED STUDY IN SOUTH KOREA

P071 Silvio Monfardini COSTS FOR CARE OF ITALIAN PATIENTS WITH LUNG CANCER ARE NOT INCREASED IN OLDER PERSONS

P072 Valery Antoine IMPACT OF COGNITIVE IMPAIRMENT ON QUALITY OF LIFE IN GERIATRIC ONCOLOGY PATIENTS

P074 Berengère Beauplet SARCOPENIA, MOBILITY, PHYSICAL ACTIVITY AND POST-OPERATIVE RISK OF BLADDER CARCINOMA IN THE ELDERLY (SAMPHYR)

P075 Cindy Borghgraef THE RELATIONSHIP BETWEEN COGNITION AND FUNCTIONAL AUTONOMY AMONG OLDER VULNERABLE PATIENTS WITH SOLID TUMORS BEFORE THE BEGINNING OF A NEW CANCER TREATMENT

P076 Rabia Boulahssass CANCER RELATED FATIGUE (CRF) BEFORE ONCOLOGIC TREATMENTS.AST-ELD STUDY, A PROSPECTIVE COHORT STUDY WITH 979 ELDERLY CANCER PATIENTS.

P077 Teresa Browne THE IMPACT OF A CANCER DIAGNOSIS ON PHYSICAL AND MENTAL HEALTH: RESULTS FROM THE IRISH LONGITUDINAL STUDY ON AGEING

P078 Bruno Castagneto A CARE PATHWAY MODEL FOR THE ELDERLY WITH CANCER: OUTCOMES IN A SERIES 75 YEARS OLD AND OLDER PATIENTS

P079 Lessandra Chinaglia GERIATRIC ASSESSMENT OF ELDERLY WITH CANCER: EXPERIENCE FROM TWO ONCOGERIATRIC UNITS IN BRAZIL

P080 Lisa Cooper PRELIMINARY RESULTS IN DEVELOPING A GERIATRIC PROGNOSTIC ASSESSMENT TOOL FOR ELDERLY PATIENTS WITH COLON AND RECTAL CANCER

P081 Richard F Dunne DEFINING CANCER CACHEXIA IN THE GERIATRIC ONCOLOGY POPULATION: A STUDY EVALUATING WEIGHT LOSS AND SARCOPENIA IN 100 OLDER ADULTS WITH CANCER.

P083 Regina Gironés Sarrió USE OF A GERIATRIC ASSESSMENT (GA) FOR THE MANAGEMENT OF ELDERLY PATIENTS WITH STAGE IV NON-SMALL CELL LUNG CANCER (NSCLC) IN CLINICAL PRACTICE. A GIDO PROSPECTIVE PROTOCOL

P084Jenifer Gomez Mediavilla

STUDY OF FRAILTY IN OLDER ADULTS AT “HOSPITAL UNIVERSITARIO DONOSTIA”

P085 Daniëlle Hultink DEVELOPMENT OF A GERIATRIC RISK STRATIFICATION MODEL FOR COLORECTAL CANCER PATIENTS

P086Stefan StarupJeppesen

IMPACT OF COMPREHENSIVE GERIATRIC ASSESSMENT ON QUALITY OF LIFE AND OVERALL SURVIVAL IN NSCLC PATIENTS TREATED WITH STEREOTACTIC BODY RADIATION THERAPY – PRELIMINARY RESULTS OF A RANDOMIZED PILOT STUDY

P087 Sonia Jiménez Mola “HIP FRACTURE IN ELDERLY WITH CANCER, IS NEEDED A DIFFERENT APPROACH?”

P088 Theodora Karnakis USING IADL-G8 TO JUSTIFY IMPLEMENTION OF A GERIATRIC ONCOLOGY TEAM IN A PRIVATE HOSPITAL IN SÃO PAULO-BRAZIL

P089 Theodora Karnakis INITIAL RESULTS OF A VALIDATION OF THE IADL-MODIFIED G8 SCALE ON A BRAZILIAN POPULATION

P090 Cindy Kenis GERIATRIC ASSESSMENT (GA)- BASED RECOMMENDATIONS AND SUBSEQUENT ACTIONS IN OLDER PATIENTS WITH CANCER

P091 Cindy Kenis GERIATRIC SCREENING AND GERIATRIC ASSESSMENT ADD INDEPENDENT PROGNOSTIC INFORMATION FOR SURVIVAL TO BASIC CLINICAL DATA IN OLDER PATIENTS WITH CANCER.

P093 Jee Hyun KimPROSPECTIVE VALIDATION OF A NOVEL GERIATRIC SCREENING TOOL, THE KOREAN CANCER STUDY GROUP GERIATRIC SCORE (KG)-7, IN OLDER PATIENTS WITH ADVANCED CANCER UNDERGOING 1ST LINE PALLIATIVE CHEMOTHERAPY

P094 Ki Hyang Kim ASSOCIATION OF MULTIDIMENSIONAL COMORBIDITIES WITH SURVIVAL AND UNPLANNED HOSPITALIZATION IN ELDERLY METASTATIC COLORECTAL CANCER PATIENTS TREATED WITH CHEMOTHERAPY

P095 Ki Hyang Kim USING HEAT MAPS TO ASSESS MULTIDIMENSIONAL ASSOCIATION OF COMORBIDITIES WITH SURVIVAL IN ELDERLY LUNG ADENOCARCINOMA PATIENTS TREATED WITH CHEMOTHERAPY


38

Final programme





P096 Gretchen Kimmick USE OF A GERIATRIC SCREENER TO IDENTIFY RESOURCE NEEDS IN COMMUNITY-BASED ONCOLOGY PRACTICE: WORK IN PROGRESS

P097 Ludmila Koch ELDERLY PATIENTS UNDERGONE HEMATOPOIETIC STEM CELL TRANSPLANTATION: BODY COMPOSITION AND ENGRAFTMENT

P098Kah Poh (Melissa) Loh

SUBJECTIVE AGE AS A CLINICALLY USEFUL INDICATOR OF IMPAIRMENT IN GERIATRIC ASSESSMENT: BASELINE DATA OF 349 OLDER PATIENTS WITH ADVANCED CANCER FROM A NATIONWIDE CLUSTER RANDOMIZED CONTROLLED TRIAL

P099Borja López De San Vicente

IMPLEMENTING A CANCER-SPECIFIC GERIATRIC ASSESSMENT FOR PATIENTS WITH ADVANCED LUNG CANCER IN A UNIVERSITY HOSPITAL.

P100 Cecilia Lund THE EFFECT OF GERIATRIC INTERVENTION IN FRAIL ELDERLY PATIENTS RECEIVING CHEMOTHERAPY FOR COLORECTAL CANCER: A RANDOMIZED TRIAL (GERICO)

P101 Josep Majó PREDICTORS OF DEATH OR HOSPITAL READMISSION OF OLDER CANCER PATIENTS DURING ADMISSION IN A ONCO-GERIATRIC INTERMEDIATE CARE UNIT

P102 Daisuke Makiura COMPARISON OF FRAILTY DETECTION AND POSTOPERATIVE MORBIDITY PREDICTION AMONG THREE GERIATRIC SCREENING TOOLS IN ELDERLY PATIENTS UNDERGOING GASTROINTESTINAL CANCER SURGERY

P103 Masahiro Matsuki INCIDENCE AND RISK FACTORS OF POSTOPERATIVE DELIRIUM IN ELDERLY PATIENTS UNDERGOING UROLOGICAL SURGERY: A MULTI- INSTITUTIONAL PROSPECTIVE STUDY

P104 Sambavy Nadaraja SIGNIFICANCE OF GERIATRIC ASSESSMENT FOR OPTIMAL TREATMENT OF OLDER CANCER PATIENTS

P105 Rei Ono IMPACT OF PREOPERATIVE GERIATRIC CONDITIONS TO PREDICT POSTOPERATIVE COMPLICATIONS IN ELDERLY CANCER PATIENTS: SARCOPENIA, COGNITIVE DECLINE, AND SOCIAL ISOLATION

P106 Marianne Ørum PERFORMANCE STATUS AND FRAILTY IN OLDER CANCER PATIENTS, A FOLLOW-UP STUDY.

P107 Elena Paillaud OBESITY SURVIVAL PARADOX IN OLDER-CANCER PATIENTS: RESULTS FROM THE PHYSICAL FRAILTY IN ELDERLY CANCER PATIENTS (PF-EC) COHORT STUDY

P108 Fernanda Maris Peria PROSPECTIVE ANALYSIS OF CHEMOTHERAPY TOXICITY RISK IN ELDERLY PATIENTS WITH COLORECTAL CANCER AND ITS CORRELATION WITH PREDICTIVE MODEL PROPOSED BY HURRIA AND COLEAGUES.

P109 Chiara Russo COULD ONCOLOGICAL (ECOG PS), GERIATRIC (CGA) AND ROCKWOOD FRAILTY INDEX EVALUATION PREDICT CHEMOTOXICITY IN ELDERLY CANCER PATIENTS?

P110 Martine Puts USE OF GERIATRIC ASSESSMENT & GERIATRIC SCREENING FOR OLDER ADULTS IN THE RADIATION ONCOLOGY SETTING: A SYSTEMATIC REVIEW

P111 Martine PutsCLINICAL AND COST-EFFECTIVENESS OF A COMPREHENSIVE GERIATRIC ASSESSMENT AND MANAGEMENT FOR CANADIAN ELDERS WITH CANCER: THE 5C STUDY. STUDY DESIGN FOR A RANDOMIZED CONTROLLED PHASE III TRIAL.

P112 Martine Extermann PERIOPERATIVE SCREENING OF THE ELDERLY PATIENT WITH HEPATOBILIARY CANCER: A PILOT STUDY

P113 Hanah Nicole Rier SEVERE SARCOPENIA IS ASSOCIATED WITH A DECLINE OF PHYSICAL INDEPENDENCE IN OLDER PATIENTS UNDERGOING CHEMOTHERAPEUTIC TREATMENT.

P115 Chiara Russo AGE, COMPREHENSIVE GERIATRIC (CGA) AND ROCKWOOD FRAILTY INDEX EVALUATION AS PREDICTORS OF SURGICAL COMPLICATIONS IN ELDERLY CANCER PATIENTS

P116Jurema Telles de Oliveira Lima Sales

A PROSPECTIVE BRAZILIAN EXPLORATORY PROGNOSTIC STUDY FOR THE DEVELOPMENT OF A PRACTICAL SCORE FOR THE EVALUATION OF THE RISK OF EARLY DEATH AND SURVIVAL IN ELDERLY CANCER PATIENTS FROM THE BROAD GERIATRIC EVALUATION

P117 Schroder Sattar HEALTH STATUS, EMERGENCY DEPARTMENT VISITS, AND ONCOLOGISTS' FEEDBACK: AN ANALYSIS OF A RANDOMIZED PHASE II GERIATRIC ASSESSMENT TRIAL

P118 Schroder Sattar THE IMPACT OF FALLS IN OLDER CANCER PATIENTS

P119Gabrielle Ribeiro Sena

PREDICTION OF EARLY DEATH IN ELDERLY PATIENTS WITH CANCER THROUGH ARTIFICIAL NEURAL NETWORK (MULTILAYER PERCEPTRON).

P120 Armin Shahrokni OLDER CANCER PATIENTS’ INTERACTION WITH THE COMPUTER TO COMPLETE ELECTRONIC PATIENT-REPORTED OUTCOME (EPRO) AND PREOPERATIVE FRAILTY.

P121 Esteban Td Souwer RISK STRATIFICATION FOR SURGICAL OUTCOMES IN OLDER COLORECTAL CANCER PATIENTS USING ISAR-HP AND G8 SCREENING TOOLS

P122 Florian Strasser PREDICTION OF DEATH, HOSPITALIZATIONS AND TOXICITY BY G8 DOMAINS IN A PROSPECTIVE COHORT STUDY: IMPORTANCE OF NUTRITIONAL INTAKE AND PERCEIVED HEALTH

YOUNGSIOG


39

Final programme





P123 Yukari Tsubata A PROSPECTIVE FEASIBILITY STUDY AND CONSTRUCTION OF REGIONAL CO-OPERATION NETWORK FOR THE ELDERLY THORACIC MALIGNANCY PATIENTS USING COMPREHENSIVE GERIATRIC ASSESSMENT (CGA) TOOLS.

P124 Fiammetta Ugolini OUR EXPERIENCE OF A JOINT GERIATRIC ONCOLOGY CLINIC FOR THE MANAGEMENT OF ELDERLY WOMEN DIAGNOSED WITH BREAST CANCER.

P125Gouri Shankar Bhat-tacharyya

PREDICTOR OF SURVIVAL IN GERIATRIC PATIENTS WITH NON SMALL CELL LUNG CANCER IN RESOURCE CONSTRAINT SITUATION

P126 Antoine Valery IMPACT OF A CLINICAL PHARMACIST-GERIATRICIAN TEAMWORK ON MEDICATION REVIEW IN GERIATRIC ONCOLOGY PATIENTS

P127 Divyanshu Dua DEVELOP A SERVICE MODEL FOR A GERIATRIC ONCOLOGY CLINIC WITH CANCER SOCIAL WORKER CO-ORDINATION.

P128 Theodora Karnakis FIVE YEARS’ EXPERIENCE OF GERIATRIC ONCOLOGY TEAM AT CANCER INSTITUTE OF SÃO PAULO-ICESP.

P129 Idoia Morilla ONCOGERIATRICS IN SPAIN. RESULTS OF THE SPANISH ONCOGERIATRY TASK FORCE NATIONAL SURVEY.

P130Ewa Franciszka Szu-macher

NATIONAL SURVEY AMONG RADIATION ONCOLOGY RESIDENTS RELATED TO THEIR NEEDS IN GERIATRIC ONCOLOGY

P131 Ya-Ling Yang QUALITY OF LIFE AND THE INFLUENCING FACTORS IN ELDERLY WOMEN WITH OVARIAN CANCER

P132 Tomonori Mizutani DECISION MAKING CAPACITY IN GERIATRIC CANCER TRIALS

P133 Elena Paillaud PREFERENCES ABOUT SURROGATE DESIGNATION AND DECISION MAKING PROCESS IN OLDER VERSUS YOUNGER ADULTS PATIENTS WITH CANCER: A COMPARATIVE CROSS-SECTIONAL STUDY

P134 Ankit Anand IMPACT OF AGE AND COMORBIDITY ON ACCEPTANCE OF CHEMOTHERAPY IN PATIENTS WITH HIGH RISK LOCALIZED PROSTATE CANCER

P135 Valery Antoine SOCIO-DEMOGRAPHICAL AND MEDICAL CHARACTERISTICS OF VERY OLD ONCOLOGY PATIENTS ASSOCIATED WITH DECREASED QUALITY OF LIFE

P136 Valery Antoine WHAT IS QUALITY OF LIFE FOR VERY OLD GERIATRIC ONCOLOGY PATIENTS?

P137 Concepcion Boque FUNCTIONAL IMPACT AND NEED OF GERIATRIC RESOURCES IN HOSPITALIZED ELDERLY PATIENTS WITH HEMATOLOGICAL MALIGNANCIES

P139 Fernanda Maris Peria ANALYSIS OF PRACTICE OF DRUGS CONCILIATION IN ELDERLY ´PATIENTS WITH CANCER

*Please note that the following posters have been withdrawn: P001, P006, P009, P015, P023, P024, P027, P031, P033, P034, P036, P045, P,053, P054, P057, P061, P073, P082, P092, P114, P138.


40

Final programme


Multinational Associationof Supportive Care in Cancer

41

Final programme



Sponsors acknowledgementThe International Society of Geriatric Oncology thanks all sponsors and exhibitors for their support towards the 2017 Annual Conference.

Educational grantsWe gratefully acknowledge the following companies for their unrestricted educational grants towards our scientific programme.The following session has been supported by and unrestricted education grant by Sanofi Genzyme:

Warsaw IV & V

14:45-15:45 Educational session: Update of the treatment Chairs: Nicolas Mottet (FR) of prostate cancer in the elderly and Eleni Efstathiou (GR/US)

14:45-15:00 Urological aspects and application of SIOG guidelines Nicolas Mottet (FR)

15:00-15:15 Consensus of the Advanced Prostate Cancer Iwona Skoneczna (PL) Conference 2017 (St. Gallen, CH)

15:15-15:30 Presentation of the outstanding phase III trials: Eleni Efstathiou (GR/US) ASCO 2017 (Latitude and Stampede)

15:30-15:45 Case discussion Shabbir Alibhai (CA)

The following session has been supported by and unrestricted education grant by BTG/TheraSphere and Varian Medical Systems:

DAY 2 - Friday , November 10, 2017Warsaw IV & V

09:30-11:00 Educational session: Chairs: Daniel Anaya (US) Liver cancer in the elderly and Sarah Hoffe (US)

09:30-09:50 Liver cancer: a common and reversible Lodovico Balducci (US) cause of mortality in older patients

09:50-10:10 Surgical treatment of primary and secondary liver cancer Daniel Anaya (US)

10:10-10:30 A radiation oncology perspective Jessica Frakes (US)

10:30-10:50 Interventional radiology and the management of liver cancer Junsung Choi (US)

10:50-11:00 Conclusions Sarah Hoffe (US)


42

Final programme


Right Medicine Right Patient Right Time

Don’t miss Clinigen’s satellite symposium - Re-Evaluating The Role of Dexrazoxane

on Saturday 11th November 2017

Clinigen Group exists to deliverthe right medicine,to the right patient, at the right time to improve the quality of people’s lives around the world.

www.clinigengroup.com

C

M

Y

CM

MY

CY

CMY

K

Int Soc Geriatric Oncology 17artwork.pdf 1 26/09/2017 10:43

43

Final programme


Scientific displays at SIOG 2017An open space within the poster area had been provided for industry partners to setup a scientific display showcase.Come and join them during the coffee breaks which will take place in this open space promoting frequent and repeated opportunities for delegates to visit the posters and scientific displays.

Exhibition opening hoursThursday, November 9 10:00-19:00Friday, November 10 09:30-17:30Saturday, November 11 09:30-15:00

The following industry sponsored satellite session is being organized by Clinigen:

DAY 3 - Saturday, November 11, 2017Warsaw IV&V

10:30-11:30 Re-evaluating dexrazoxane Chair: Etienne Brain (FR)

10:30-10:40 Welcome and introduction Etienne Brain (FR)

10:40-11:00 Clinical indications for dexrazoxane as Robin Jones (GB) a cardioprotective agent

11:00-11:20 Cardioprotection in elderly patients Steven E Lipshultz (US)

11:20-11:30 Summary and questions

Industry sponsored satellitesession programme

Official media partners


Right Medicine Right Patient Right Time

Don’t miss Clinigen’s satellite symposium - Re-Evaluating The Role of Dexrazoxane

on Saturday 11th November 2017

Clinigen Group exists to deliverthe right medicine,to the right patient, at the right time to improve the quality of people’s lives around the world.

www.clinigengroup.com

C

M

Y

CM

MY

CY

CMY

K

Int Soc Geriatric Oncology 17artwork.pdf 1 26/09/2017 10:43

44

Final programme


Sponsor and exhibitor profiles

AIOTE (Italian Society of Geriatric Oncology)Medical Oncology Unit, Umberto - Hospital, Siracusa, Italy - www.aiote.net

The aims of this society is (a) to promote training activities for both clinical oncologists and geriatricians, in order to improve their cooperation for a better management of elderly patients, (b) to increase the knowledge about cancer disease in elderly population, thus avoiding the discrimination of these patients who often receive inappropriate treatment, and, finally, (c) to educate elderly patients to cope better with the disease. Visit us in the poster and exhibition area.

AMGENDammstrasse 23, 6300 Zug, Switzerland - www.amgen.com

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Our belief-and the core of our strategy-is that innovative, highly differentiated medicines that provide large clinical benefits in addressing serious diseases are medicines that will not only help patients, but also will help reduce the social and economic burden of disease in society today. Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology innovator since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

BTG International LTDMain Office, 5 Fleet Place, London EC4M 7RD, United Kingdom - www.btgplc.com

At BTG we are focused on developing innovative products in specialist areas of medicine to better serve doctors and patients. Our growing portfolio of Interventional Medicine products is designed to advance the treatment of cancer, severe emphysema, severe blood clots, and varicose veins, while our Specialty Pharmaceuticals portfolio offers antidotes that alleviate toxicity and treat rare conditions. Our competitive advantage is our dedication to finding smart, often unconventional solutions to complex medical problems. Many of our products combine medicines, device technology and new techniques in order to deliver more targeted treatments. We also invest in the clinical evidence that helps demonstrate the value of our products to doctors, patients, and healthcare systems. Whether developed in our own labs or in partnership with clinicians, academics, and other companies, we believe passionately that medical innovation has the power to improve human health.

CelgeneRoute de Perreux 1,2017 Boudry, Switzerland - www.celgene.com

Celgene is a global biopharmaceutical company committed to improving the lives of patients worldwide. We seek to deliver truly innovative and life-changing drugs for our patients through the discovery, development, and commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions. Celgene employs more than 7,000 employees worldwide.

ClinigenPitcairn House, Crown Square, First Avenue, Burton-on-Trent, Staffordshire DE14 2WW,Great Britain - www.clinigengroup.com

Clinigen Group plc is a rapidly-growing global specialty pharmaceutical and services company with a unique combination of businesses focused on delivering the right medicine to the right patient at the right time to improve the quality of people’s lives around the world. The Group consists of five synergistic businesses focused in three areas of global medicine supply: clinical trial, unlicensed and licensed medicines. Our group of complementary businesses can operate efficiently in a complex global regulatory environment and can ensure that precious medicines are delivered securely and effectively, wherever they are needed throughout the product lifecycle. Through five businesses, Clinigen Clinical Trial Services, Idis Managed Access, Idis Global Access, Link Healthcare and Clinigen Specialty Pharmaceuticals, we provide patient access to our own and other pharmaceutical companies’ products, whether to meet unmet medical needs or for use in clinical trials.'


45

Final programme


ecancer13 King Square Avenue, Bristol, BS2 8HU - United Kingdom - www.ecancer.org

ecancer is a not for profit, independent organisation with over 10 years' experience in providing easily accessible educational content free to the global oncology community. We believe in removing financial barriers to accessing research and education. To do this we created ecancer.org, a vast online knowledge bank incorporating an open-access journal, news, video and e-learning (in both English and Spanish). All of our resources are available for free and have been developed in partnership with leading global experts and focus on supporting healthcare professionals to improve their practice behaviours to get the best outcomes for patients.

Elsevier / Journal of Geriatric OncologyThe Boulevard, Langford Lane, Kidlington - Oxford, OX5 1GB - United Kingdom - www.elsevier.com

The Journal of Geriatric Oncology - published by Elsevier - the official journal of the International Society of Geriatric Oncology - is an international, multidisciplinary journal which is focused on advancing research in the treatment and survivorship issues of older adults with cancer, as well as literature relevant to education and policy development in geriatric oncology. The journal publishes original research articles, review articles, clinical trials, short communications and correspondence.

Helsinn Heathcare SAVia Pian Scairolo 9, 6912 Lugano/Pazzallo, Switzerland - www.helsinn.com

Helsinn is a privately owned pharmaceutical group with an extensive portfolio of marketed cancer care products and a robust drug development pipeline. Since 1976, Helsinn has been improving the everyday lives of patients, guided by core family values of respect, integrity and quality. The Group works across pharmaceuticals, biotechnology, medical devices and nutritional supplements and has expertise in research, development, manufacture and the commercialization of therapeutic and supportive care products for cancer, pain and inflammation and gastroenterology. In 2016, Helsinn created the Helsinn Investment Fund to support early-stage investment opportunities in areas of unmet patient need. The company is headquartered in Lugano, Switzerland, with operating subsidiaries in Switzerland, Ireland and the US, a representative office in China as well as a product presence in approximately 190 countries globally. For more information, please visit www.helsinn.com

Janssen Pharmaceutica NV Turnhoutseweg 30 - B-2340 Beerse - Belgium - www.janssen-emea.com

At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science. We are Janssen. We collaborate with the world for the health of everyone in it. Learn more at www.janssen.com/emea. Follow us on www.twitter.com/janssenEMEA for our latest news.

Multinational Association of Supportive Care in Cancer (MASCC)215 Spadina Ave, Suite 400, Toronto, ON, M5T 2C7, Canada - www.mascc.org

The Multinational Association of Supportive Care in Cancer (MASCC) is a multidisciplinary organization dedicated to research and education of supportive care professionals worldwide. The mission of MASCC is to improve the supportive care of people with cancer, from diagnosis, through treatment and survival to the end of life. Founded in 1990, MASCC now includes members from more than 70 countries. Because supportive care encompasses all aspects of care, it involves a variety of disciplines and specialists. Membership is open to medical, surgical, and radiation oncologists, nurses, dentists, dental hygienists, pharmacists, social workers, dietitians, and others interested in supportive care in cancer. Visit us in the poster and exhibition area.


46

Final programme


Pfizer OncologyLinkstr. 10, 10785 Berlin, Germany - www.pfizer.de

Pfizer Oncology is committed to pursuing innovative treatments that have a meaningful impact on those living with cancer. As a leader in oncology speeding cures and accessible breakthrough medicines to patients, Pfizer Oncology is helping to redefine life with cancer. Our strong pipeline of biologics, small molecules and immunotherapies, one of the most robust in the industry, is studied with precise focus on identifying and translating the best scientific breakthroughs into clinical application for patients across a wide range of cancers. By working collaboratively with academic institutions, individual researchers, cooperative research groups, governments and licensing partners, Pfizer Oncology strives to cure or control cancer with its breakthrough medicines. Because Pfizer Oncology knows that success in oncology is not measured solely by the medicines you manufacture, but rather by the meaningful partnerships you make to have a more positive impact on people’s lives. Learn more about how Pfizer Oncology is applying innovative approaches to improve the outlook for people living with cancer at http://www.pfizer.com/research/therapeutic_areas/oncology.

Pierre Fabre Group45, Place Abel Gance - Boulogne Billancourt 92654 - France - www.pierre-fabre.com

Pierre Fabre is a French multinational, privately-owned pharmaceutical and cosmetic company present in 130 countries. Pierre Fabre’s oncology know-how is based on decades of experience in the discovery, development and global commercialization of innovative cancer drugs including monoclonal antibodies and natural cytotoxic agents. Pierre Fabre oncology R&D centers are Pierre Fabre Immunology Centre (CIPF) in Saint-Julien-en-Genevois, France and Pierre Fabre Research Institute (IRPF) in Toulouse, France. For more information on Pierre Fabre, please visit www.pierre-fabre.com

RocheGrenzacherstrasse 124 - 4070 Basel - Switzerland - www.roche.com

The Roche Group is the world's leading provider of cancer care products. Our anti-cancer medicines are saving lives and significantly advancing the way some cancers are treated. In addition, Roche is developing new diagnostic tests that will have a significant impact on disease management for cancer patients in the future. With a broad portfolio of tumour markers as well as a range of molecular oncology tests, Roche will continue to be one of the leaders in providing cancer-focused treatments and diagnostics. Roche - Doing now what patients need next.

Sanofi Genzyme54 Rue de la Boetie - 75008 Paris - France - www.sanofi.com

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Merial. Sanofi Genzyme focuses on developing specialty treatments for debilitating diseases that are often difficult to diagnose and treat, providing hope to patients and their families.

SIOG - International Society of Geriatric Oncology1-5 Route des Morillons - P.O. Box 2100 - 1211 Geneva - Switzerland - www.siog.org

The International Society of Geriatric Oncology is a multidisciplinary society, including physicians in the fields of oncology and geriatrics, and allied health professionals and has over 1,500 members in more than 93 countries around the world. The major risk factor for cancer is age, and with the aging of the world population, a major epidemiologic challenge is before us. The mission of SIOG is to foster the development of health professionals in the field of geriatric oncology, in order to optimize treatment and care of older adults with cancer. Learn more about SIOG at www.siog.org. Visit us in the poster and exhibition aera.

Varian Medical Systems3100 Hansen Way, Palo Alto, CA 94304, United States - www.varian.com

Varian Medical Systems focuses energy on saving lives by equipping the world with advanced technology for fighting cancer and other medical conditions with radiation. The company provides comprehensive solutions for radiotherapy, radiosurgery, proton therapy and brachytherapy, as well as oncology information systems for managing comprehensive cancer clinics, treatment planning software, and informatics solutions to support knowledge sharing and evidence-based medicine. Varian Medical Systems employs approximately 6,000 people who are located at manufacturing sites in North America, Europe, and China, plus some 70 sales and support offices around the world.

2016MILANITALY17-19 NOV.


47

Final programme

17th Conference of the International Society of Geriatric Oncology “From research to practice: incorporating geriatric oncology into patient care”Efficacy in three

indications

Metastatic pancreatic cancer in combination with gemcitabine for first-line treatment of adult patients

Metastatic breast cancer as monotherapy in adult patients when first-line treatment fails and anthracycline containing therapy is not indicated

Non-small cell lung cancer in combination with carboplatin for first-line treatment of adult patients when surgery and/or radiotherapy are not indicated

ABRAXANE® Abbreviated Product Information: Abraxane 5 mg/ml, powder for suspension for infusion. Refer to the Summary of Product Characteristics (SmPC) before prescribing. Qualitative and quantitative composition: Each vial contains 100 mg or 250 mg of paclitaxel formulated as albumin bound nanoparticles. After reconstitution, each ml of suspension contains 5 mg of paclitaxel formulated as albumin bound nanoparticles. Therapeutic indications: breast cancer: in monotherapy for the treatment of metastatic breast cancer in adults who have failed first-line treatment for metastatic disease and for whom standard, anthracycline containing therapy is not indicated. Pancreatic cancer: in combination with gemcitabine for the first-line treatment of adults with metastatic adenocarcinoma of the pancreas. Lung cancer: in combination with carboplatin for the first-line treatment of non-small cell lung cancer in adults who are not candidates for potentially curative surgery and/or radiation therapy. Posology and method of administration: Dose is modified based upon clinical and laboratory findings. Administer reconstituted Abraxane suspension intravenously using an infusion set incorporating a 15 μm filter. Breast cancer: 260 mg/m2 administered intravenously over 30 minutes every 3 weeks. Pancreatic cancer: 125 mg/m2 administered intravenously over 30 minutes on Days 1, 8 and 15 of each 28-day cycle in combination with gemcitabine. Lung cancer: Abraxane:100 mg/m2 administered as an intravenous infusion over 30 minutes on Days 1, 8 and 15 of each 21-day cycle in combination with carboplatin. In case adverse reactions please refer to recommendation of dose adjustments in the SmPC. Paediatric population: The safety and efficacy has not been established. Older people: No additional dosage reductions, other than those for all patients. Patients with hepatic impairment: Mild hepatic impairment (total bilirubin > 1 to ≤ 1.5 x ULN and AST ≤ 10 x ULN): no dose adjustments are required. Moderate to severe hepatic impairment (total bilirubin > 1.5 to ≤ 5 x ULN and AST ≤ 10 x ULN): a 20% reduction in dose is recommended for metastatic breast cancer patients and non-small cell lung cancer patients; the reduced dose may be escalated to the dose for patients with normal hepatic function if the patient is tolerating the treatment for at least two cycles. Patients with renal impairment: mild to moderate renal impairment (estimated creatinine clearance ≥30 to <90 ml/min): adjustment of the starting dose is not required. Contraindications: Hypersensitivity to the active substance or to any of the excipients; lactation; patients who have baseline neutrophil counts <1500 cells/mm3. Special warnings and precautions for use: Abraxane should not be substituted for or with other paclitaxel formulations, because it may have substantially different pharmacological properties compared to other formulations of paclitaxel. Hypersensitivity: Rare occurrences of severe hypersensitivity reactions, including very rare events of anaphylactic reactions with fatal outcome, have been reported. If a hypersensitivity reaction occurs, the medicinal product should be discontinued immediately, symptomatic treatment should be initiated, and the patient should not be rechallenged with paclitaxel. Haematology: Frequent monitoring of blood cell counts should be performed. Patients should not be retreated with subsequent cycles until neutrophils recover to >1500 cells/mm3 and platelets recover to >100,000 cells/mm3. Neuropathy: Abraxane in monotherapy: if Grade 3 sensory neuropathy develops, treatment should be withheld until resolution to Grade 1 or 2 followed by a dose reduction for all subsequent courses. Abraxane in combination with gemcitabine: if Grade 3 or higher peripheral neuropathy develops, withhold Abraxane; continue treatment with gemcitabine at the same dose; resume Abraxane at reduced dose when peripheral neuropathy improves to Grade 0 or 1. Abraxane in combination with carboplatin: if Grade 3 or higher peripheral neuropathy develops, treatment should be withheld until improvement to Grade 0 or 1 followed by a dose reduction for all subsequent courses of Abraxane and carboplatin. Sepsis: If a patient becomes febrile (regardless of neutrophil count), initiate treatment with broad spectrum antibiotics. For febrile neutropenia, withhold Abraxane and gemcitabine until fever resolves and ANC ≥ 1500 cells/mm3, then resume treatment at reduced dose levels. Pneumonitis: Closely monitor all patients for signs and symptoms of pneumonitis. After ruling out infectious etiology and upon making a diagnosis of pneumonitis, permanently discontinue treatment with Abraxane and gemcitabine and promptly initiate appropriate treatment and supportive measures. Hepatic impairment: Administration of Abraxane should be performed with caution because of the increased risk of toxicity, particularly myelosuppression and patients should be closely monitored for development of profound myelosuppression. Abraxane is not recommended in patients that have total bilirubin > 5 x ULN or AST > 10 x ULN. In addition, Abraxane is not recommended in patients with metastatic adenocarcinoma of the pancreas that have moderate to severe hepatic impairment (total bilirubin > 1.5 x ULN and AST ≤ 10 x ULN).

Cardiotoxicity: Patients receiving Abraxane should be vigilantly monitored by physicians for the occurrence of cardiac events. CNS metastases: The effectiveness and safety of Abraxane in patients with central nervous system (CNS) metastases has not been established. Gastrointestinal symptoms: If patients experience nausea, vomiting and diarrhoea following the administration of Abraxane, they may be treated with commonly used anti-emetics and constipating agents. Cystoid macular oedema: treatment with Abraxane should be discontinued. Contraception in males and females: Women of childbearing potential should use effective contraception during treatment and up to 1 month after receiving treatment with Abraxane. Male patients treated with Abraxane are advised not to father a child during and up to six months after treatment. Fertility: Male patients should seek advice on conservation of sperm prior to treatment because of the possibility of irreversible infertility due to therapy with Abraxane. Patients 75 years and older: Patients should be carefully assessed for their ability to tolerate Abraxane in combination with gemcitabine with special consideration to performance status, co-morbidities and increased risk of infections. Excipients: When reconstituted, each ml of Abraxane concentrate contains 0.183 mmol sodium, which is 4.2 mg of sodium. Preparation and administration: Use of filters with a pore size less than 15 μm may result in blockage of the filter. Interactions with other medicinal products and other forms of interaction: Abraxane is indicated as monotherapy for breast cancer, in combination with gemcitabine for pancreatic adenocarcinoma, or in combination with carboplatin for non-small cell lung cancer and should not be used in combination with other anticancer agents. Caution should be exercised when administering concomitantly with medicines known to inhibit either CYP2C8 or CYP3A4 (e.g. ketoconazole and other imidazole antifungals, erythromycin, fluoxetine, gemfibrozil, clopidogrel, cimetidine, ritonavir, saquinavir, indinavir, and nelfinavir) because toxicity of paclitaxel may be increased due to higher paclitaxel exposure. Administering paclitaxel concomitantly with medicines known to induce either CYP2C8 or CYP3A4 (e.g. rifampicin, carbamazepine, phenytoin, efavirenz, nevirapine) is not recommended because efficacy may be compromised because of lower paclitaxel exposures. Pregnancy and breast-feeding: Abraxane should not be used in pregnancy, and in women of childbearing potential not using effective contraception (risk of serious birth defects), unless the clinical condition of the mother requires treatment with paclitaxel. Breast-feeding must be discontinued for the duration of therapy. Effects on ability to drive and use machines: Patients should be advised not to drive and use machines if they feel tired or dizzy. Overdose: Patient should be closely monitored. Treatment should be directed at the major anticipated toxicities, which are bone marrow suppression, mucositis and peripheral neuropathy. Adverse reactions: Abraxane monotherapy: Infection, urinary tract infection, folliculitis, upper respiratory tract infection, candidiasis, sinusitis, oral candidiasis, nasopharyngitis, cellulitis, herpes simplex, viral infection, pneumonia, catheter-related infection, fungal infection, herpes zoster, injection site infection, sepsis (including neutropenic sepsis), metastatic pain, tumour necrosis, neutropenia, anaemia, leukopenia, thrombocytopenia, lymphopenia, bone marrow suppression, febrile neutropenia, pancytopenia, hypersensitivity, severe hypersensitivity, anorexia, dehydration, decreased appetite, hypokalaemia, hypophosphataemia, fluid retention, hypoalbuminaemia, polydipsia, hyperglycaemia, hypocalcaemia, hypoglycaemia, hyponatraemia, insomnia, depression, anxiety, restlessness, peripheral neuropathy, neuropathy, hypoaesthesia, paraesthesia, peripheral sensory neuropathy, headache, dysgeusia, dizziness, peripheral motor neuropathy, ataxia, sensory disturbance, somnolence, olyneuropathy, areflexia, dyskinesia, hyporeflexia, neuralgia, sensory loss, syncope, postural dizziness, neuropathic pain, tremor, increased lacrimation, blurred vision, dry eye, keratoconjunctivitis sicca, madarosis, eye irritation, eye pain, abnormal vision, reduced visual, acuity, conjunctivitis, visual disturbance, eye pruritus, keratitis, cystoid macular oedema, vertigo, ear pain, tinnitus, tachycardia, arrhythmia, supraventricular tachycardia, bradycardia, cardiac arrest, left ventricular dysfunction, congestive, heart failure, atrioventricular block, flushing, hot flushes, hypertension, lymphedema, hypotension, peripheral coldness, orthostatic hypotension, thrombosis, interstitial pneumonitis, dyspnoea, epistaxis, pharyngolaryngeal, pain, cough, rhinitis, rhinorrhoea, productive cough, exertional dyspnoea, sinus congestion, decreased breath sounds, pleural effusion, allergic rhinitis, hoarseness, nasal congestion, nasal dryness, wheezing, pulmonary emboli, pulmonary thromboembolism, nausea, diarrhoea, vomiting, constipation, stomatitis, abdominal pain, abdominal distension, upper abdominal pain, dyspepsia, gastrooesophageal reflux disease, oral hypoaesthesia, dysphagia, flatulence, glossodynia, dry mouth, gingival pain, loose stools, oesophagitis, lower abdominal pain, mouth

ulceration, oral pain, rectal haemorrhage, hepatomegaly, alopecia, rash, nail disorder, pruritus, dry skin, erythema, nail pigmentation/discolouration, skin hyperpigmentation, onycholysis, nail changes, nail bed tenderness, urticaria, skin pain, photosensitivity reaction, pigmentation disorder, pruritic rash, skin disorder, hyperhidrosis, onychomadesis, erythematous rash, generalised rash, dermatitis, night sweats, maculo-papular rash, vitiligo, hypotrichosis, nail discomfort, generalized pruritus, macular rash, papular rash, skin lesion, swollen face, Stevens-Johnson syndrome, toxic epidermal necrolysis, arthralgia, myalgia, pain in extremity, bone pain, back pain, muscle cramps, limb pain, chest wall pain, muscular weakness, neck pain, groin pain, muscle spasms, musculoskeletal pain, flank pain, limb discomfort, muscle weakness, dysuria, pollakiuria, haematuria, nocturia, polyuria, urinary incontinence, breast pain, fatigue, asthenia, pyrexia, peripheral oedema, mucosal inflammation, pain, rigors, oedema, weakness, decreased performance status, chest pain, influenza-like illness, malaise, lethargy, hyperpyrexia, chest discomfort, abnormal gait, swelling, injection site reaction, extravasation, decreased weight, increased alanine aminotransferase, increased aspartate aminotransferase, decreased haematocrit, decreased red blood cell count, increased body temperature, increased gamma-glutamyltransferase, increased blood alkaline phosphatase, increased blood pressure, increased weight, increased blood lactate dehydrogenase, increased blood creatinine, increased blood glucose, increased blood phosphorus, decreased blood potassium, increased bilirubin, contusion, radiation recall phenomenon, radiation pneumonitis. Abraxane in combination with gemcitabine: sepsis, pneumonia, oral candidiasis, neutropenia, anaemia, thrombocytopenia, pancytopenia, thrombotic thrombocytopenic purpura, dehydration, decreased appetite, hypokalaemia, insomnia, depression, anxiety, peripheral neuropathy, dysgeusia, headache, dizziness, VIIth nerve paralysis, lacrimation increased, cystoid macular oedema, cardiac failure congestive, tachycardia, hypotension, hypertension, dyspnoea, epistaxis, cough, pneumonitis, nasal congestion, dry throat, nasal dryness, nausea, diarrhoea, vomiting, constipation, abdominal pain, abdominal pain upper, stomatitis, intestinal obstruction, colitis, dry mouth, cholangitis, alopecia, rash, pruritus, dry skin, nail disorder, flushing, pain in extremity, arthralgia, myalgia, muscular weakness, bone pain, acute renal failure, haemolytic uraemic syndrome, fatigue, oedema peripheral, pyrexia, asthenia, chills, infusion site reaction, weight decreased, alanine aminotransferase increased, aspartate aminotransferase increased, blood bilirubin increased, blood creatinine increased. Abraxane in combination with carboplatin: pneumonia, bronchitis, upper respiratory tract infection, urinary tract infection, sepsis, oral candidiasis, neutropenia1, thrombocytopenia, anaemia, leukopenia, febrile neutropenia, lymphopenia, pancytopenia, drug hypersensitivity, hypersensitivity, decreased appetite, dehydration, insomnia, peripheral neuropathy, dysgeusia, headache, dizziness, vision blurred, hypotension, hypertension, flushing, dyspnea, haemoptysis, epistaxis, cough, pneumonitis, diarrhoea, vomiting, nausea, constipation, stomatitis, dyspepsia, abdominal pain, dysphagia, hyperbilirubinaemia, rash, alopecia, pruritus, nail disorder, skin exfoliation, dermatitis allergic, urticaria, arthralgia, myalgia, back pain, pain in extremity, musculoskeletal pain, fatigue, asthenia, oedema peripheral, pyrexia, chest pain, mucosal inflammation, infusion site extravasation, infusion site inflammation, infusion site rash, alanine aminotransferase increased, aspartate aminotransferase increased, blood alkaline phosphatase increased, weight decreased. Post-marketing experience: cranial nerve palsies, vocal cord paresis, severe hypersensitivity reactions, reduced visual acuity due to cystoid macular oedema, palmar-plantar erythrodysaesthesiae (in patients previously exposed to capecitabine). Marketing Authorisation Holder: Celgene Europe Ltd, 1 Longwalk Road, Stockley Park, Uxbridge UB11 1DB, United Kingdom. Marketing Authorisation: EU/1/07/428/001, EU/1/07/428/002. Medicinal product subject to restricted medical prescription. Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMA): http://www.ema.europa.eu.Updated: 18 September 2017 (v.25).

INT-ABR170039Date of preparation: September 2017

Abraxane is a registered trademark of Celgene Corporation

15268 ABX ESMO 210x297.indd 1 21/09/2017 11:01

48

Final programme


Speaker name Conflict of interest

Shabbir Alibhai (CA) None

Daniel Anaya (US) None

Lodovico Balducci (US) None

Gouri Shankar Bhattacharyya (IN) None

Paolo Bossi (IT) None

Federico Bozzetti (IT) None

Etienne Brain (FR) Not declared at the time of going to print

Katarzyna Broczek (PL) None

Krzysztof Bujko (PL) None

Philippe Caillet (FR) Not declared at the time of going to print

Andreas Charalambous (CY) None

Kwok-Leung Cheung (GB) Not declared at the time of going to print

Junsung Choi (US) None

Giuseppe Colloca (IT) Not declared at the time of going to print

Lore Decoster (BE) None

Nienke de Glas (NL) Not declared at the time of going to print

Eleni Efstathiou (GR/US) None

Martine Extermann (US) None

Jessica Frakes (US) None

Walter Gianni (IT) Not declared at the time of going to print

Rob Glynne-Jones (GB) Not declared at the time of going to print

Valentin Goede (DE) Not declared at the time of going to print

Fábio Gomes (PT/GB) None

Carlos Gomez-Roca (FR) None

Alastair Greystoke (GB) Consultancy fees from BMS, MSD, Pfizer and Astrazeneca

Tomasz Grodzicki (PL)Honoraria from pharmaceutical companies: Adamed, Glaxo, Servier, Krka, Polpharma

Agnieszka Gruzfeld (PL) Not declared at the time of going to print

Marije Hamaker (NL) None

Sarah Hoffe (US) None

Arti Hurria (US) Not declared at the time of going to print

Muhammad Shahid Iqbal (GB) Honorarium from Ipsen for clinician steering committee role

Michael Jaklitsch (US) None

Theodora Karnakis (BR) None

Charles Kelly (GB) None

Cindy Kenis (BE) Not declared at the time of going to print

Mandy Kiderlen (NL) Not declared at the time of going to print

Karis Kin-Fong Cheng (SG) None

Beatriz Korc-Grodzicki (US) None

Domenico La Carpia (IT) Not declared at the time of going to print

Stuart Lichtman (US) None

Rosa Liperoti (IT) None

Kah Poh Loh (US) None

Faculty disclosures


49

Final programme



First name Disclosure of Interest

Ronald Maggiore (US) None

Lisa McCann (GB) None

Supriya Mohile (US) None

Nicolas Mottet (FR) None

Karen Mustian (US) None

Shane O'Hanlon (GB) None

Ulrika Östlund (SE) None

Demetris Papamichael (CY) None

Christopher Plummer (GB)

Dr Plummer has received honoraria and travel expenses for speaking at educational meetings and contributing to the design and safety of clinical trials from Amgen, Clinigen, Novartis, Pfizer and Roche.

Adam Pluzanski (PL) None

Martine Puts (CA) None

Morten Quist (DK) None

Carla Ripamonti (IT) None

Jarred Rosenberg (CA)Research Support from Michael Garron Hospital Foundation, Janssen Pharmaceutical Companies of Johnson & Johnson

Siri Rostoft (NO) None

Harm Rutten (NL) None

Schroder Sattar (CA) None

Armin Shahrokni (US) None

Iwona Skonecza (PL) None

Pierre Soubeyran (FR) Not declared at the time of going to print

Reinhard Stauder (AT) None

Petra Stolz-Baskett (NZ) Not declared at the time of going to print

William Tew (US) None

Diane Tilmant-Tatischeff (FR) None

Barbara Van Leeuwen (NL) None

Hans Wildiers (BE) None

Tanya Wildes (US) None

Faculty disclosures

50

Final programme



Notes

ww

w.s

iog

.org

Save the date!November 16-18, 2018Amsterdam, The Netherlands

18th Conference of theInternational Society of Geriatric Oncology

2018AMSTERDAMTHE NETHERLANDS16-18 NOV

Member of

More women than ever are surviving early breast cancer or living longer with metastatic disease. These women need healthcare policies that support both access to treatment and a return to their normal lives, including rejoining the workforce. Visit www.EIUperspectives.economist.com/healthcare/breast-cancer-eu-workforce to learn how we can better support these women as they return to work.

The Road to a Better Normal: Breast cancer

patients and survivors in the European Union

workforce

Data analysis used to build The Road to a Better Normal report was independently led by The Economist Intelligence Unit and sponsored by Pfizer.

Documents

Final programme - SIOG | International Society of …siog.org/files/public/siog_2017_final_programme_lr.pdfFinal programme 17th Conference of the International Society of Geriatric